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Abstract
Cancer treatment by adoptive immune cell therapy (AIT) is a form of immunotherapy that
relies on the in vitro activation and/or expansion of immune cells. In this approach, immune cells,
particularly CD8+ T lymphocytes, can potentially be harvested from a tumor-bearing patient, then
activated and/or expanded in vitro in the presence of cytokines and other growth factors, and then
transferred back into the same patient to induce tumor regression. AIT allows the in vitro
generation and activation of T-lymphocytes away from the immunosuppressive tumor
microenvironment, thereby providing optimum conditions for potent anti-tumor activity.
The overall objective of this study is to: a) develop multi-modality (optical- and
radionuclide-based) molecular imaging approaches to study the overall kinetics of labeled
adoptively transferred T- lymphocytes in vivo, b) to non-invasively image and assess in-vivo,
targeting and retention of adoptively transferred labeled T-lymphocytes at the tumor site.
T-lymphocytes obtained from draining lymph nodes of 4T1 (murine breast cancer cell)
sensitized BALB/C mice were activated in vitro with Bryostatin/ Ionomycin for 18 hours, and
were grown in either Interleukin-2 (IL-2) or combination of Interleukin-7 and Interleukin-15 (IL7/IL-15) for 13 days, (cells grown in IL-2 called IL2 cells, and cells grown in IL7/15 called
IL7/15 cells). In order to validate the methodology and to offer future clinical translation, both
direct and indirect cell labeling methods were expanded and employed. The first method was
based on direct in vitro cell labeling by lipophilic near-infrared (NIR) fluorescent probe, 1,1dioctadecyltetramethyl indotricarbocyanine iodide, (DiR), followed by intravenous (i.v.) injection
into BALB/C mice for multi-spectral fluorescence imaging (MSFI). The second method was
based on indirect labeling of T- lymphocytes

through transduction of a reporter gene (cell

cytoplasm labeling Herpes Simplex Virus type 1- thymidine kinase (HSV-1 tk). The product of
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this reporter gene is an enzyme (HSV-1TK) which phosphorylates a radio labeled substrate 2fluoro-2-deoxy-1 β- D- arabinofuranosyl-5-iodouracil ([124I]-FIAU) for Positron Emission
tomography (PET) imaging.
ATP based cell viability assay, flow cytometry and interferon-γ (IFN-γ) ELISA were used
to investigate if there are any changes in cell viability, proliferation and function respectively,
before and after direct and indirect labeling. The results showed that cell viability, proliferation,
and function of labeled 4T1 specific T-lymphocytes were not affected by labeling for direct
labeling methods at DiR concentration of 320µg/ml. For the indirect labeling method, the viability
and proliferation results showed that cell viability decreases as multiplicity of infectious (MOI)
increases. In particular, at MOI of 10 almost all cells die 3 days post transduction. At MOI of 5,
cells viability was ≤ 30% and at MOI of 2 was ≤ 60%. Cell viability was 80% at MOI of 1.
The results of optical imaging were as follows: when the recipient mice with established
4T1 tumors were injected with DiR labeled 4T1 specific T-lymphocytes, the 4T1 specific Tlymphocytes (IL2 cells) infused into tumor-bearing mice showed high tumor retention, which
peaked 3 or 6 days post infusion depending on the tumor size and persisted at the tumor site for 3
weeks. In contrast, IL7/15 cells showed lower signal at the tumor site and this peaked on day 8.
On the other case when 4T1 tumor cells were implanted 1-week post-infusion of labeled Tlymphocytes. IL2 T-lymphocytes moved out of lymphoid compartments to the site of subsequent
4T1 inoculation within two hours and peaked on day 3 and the signal persisted for 2 more weeks.
In contrast with infusion of IL7/15 cells, the signal was barely detected and did not show a similar
trafficking pattern as with IL2 cells.
The results of the indirect labeling method, PET reporter gene (PRG) system (HSV-1tk /
[124I ] FIAU ) showed that both IL2 and IL7/15 cells were successfully transduced as verified ex
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vivo by real time PCR and western blot. T Cells transduction efficiency was assessed from cell
uptake study in comparison to stable transduced Jurkat cells which have transduction efficiency of
100 %. Both IL2 and IL7/15 cells showed lower transduction efficiency (≤ 30%) compared to
Jurkat cells. Consequently, PET imaging did not show a detectable signal of transduced T cells in
vivo. Biodistribution study was carried out on day 3 post [124I]-FIAU injections. Results were
consistent with the optical imaging results, except for IL7/15 cells. Transduced and untransduced
IL2 and IL7/15 cells were labeled with DiR and injected ( i.v.) into Balb / C mice and then
imaged by both imaging modalities (MSFI and PET) at the same time. MSFI images of
transduced IL2 cell showed detectable signal starting from 2 hours, peaked at 72 hours and
persisted up to 2 weeks, while IL7/15 cells were detectable at the tumor site starting at 24 hours,
peaked at 72 hours and persisted up to 2 weeks. By the end of this study animals were dissected
and tissue activities were counted using gamma counting and expressed as % Injected dose/gram
of tissue (%ID/gm). Transduced IL2 and IL7/15 cells showed higher %ID/gm than other organs at
lungs, liver, spleen, tumor, lymph nodes and bone/bone marrow. IL7/15 cells compared to IL2
cells showed higher %ID/gm at same organs. Neither IL2 nor IL7/15 untransduced DiR labeled
cells showed any activity at tumor site, and their activities at other organs was very low compared
to transduced cells.
To investigate whether labeled T-lymphocytes will localize at tumor metastases or not,
and to study the difference in their migration patterns to the tumor site versus tumor metastases,
4T1 tumor cells were successfully transduced with HSV-1tk as confirmed by RT-PCR , western
blot and cell uptake study. Transduced 4T1 cells were implanted in the right flank or in the
mammary fat pad of the mouse. Serial PET imaging was carried out in the third and fourth week
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post tumor implantation to know when the tumor will metastasizes. PET imaging showed only
signal at the tumor site and no metastasis were detected.
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Chapter One: Statement of Aims
1.1Objectives
The overall objective of this project is to develop multi-modality in vivo imaging to study
the kinetics of labeled immune cells particularly T-lymphocytes sensitized specifically to inhibit
4T1 breast carcinoma tumor growth using Optical and PET imaging. This project intends to
address the following questions:

•

What are the differences between T-lymphocytes grown in IL-2 versus IL7/15 in their

migration patterns? (Where do they localize, when do they localize at tumor site, how long they
persist, and do they retain their proliferation and functional abilities?)

•

What are the differences between direct and indirect labeling methods in terms of their

specificity and sensitivity?

•

Do T-lymphocytes localize at the tumor metastases? What are the differences in T-cell

homing between primary tumor and metastases?

1.2. Specific aims
1)

To compare direct and indirect T-cell labeling methods, in terms of their specificity
and sensitivity.
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2)

Using quantitative multi-modality (optical and PET) imaging the proliferation,
trafficking and persistence of immune cells at various time points in vivo will be
studied.

3)

To compare the trafficking and homing of T-cells grown in IL-2 versus cells grown in
the combination of IL-7 and IL-15.

4)

To investigate the differences in trafficking and homing capabilities of labeled Tlymphocytes at primary tumor versus tumor metastases.

1.3. Significant and impact
Information from this project could provide direct in vivo data on delivery, localization,
retention, and function of labeled immune cells within the context of adoptive immune cell
therapy. This information is vital to understand the in vivo trafficking behavior to guide
translation of immune cell therapy in the clinical setting.

1.4. Innovation
This work is novel in two important aspects:
1)

Employing two different imaging modalities to study the trafficking and homing of Tlymphocytes grown in different cytokines (IL-2 versus the combination of IL7and IL15).

2)

Applying two different imaging modalities to image labeled T-lymphocytes and
labeled 4T1 tumor in the same animal at the same time to know the difference in their
migration pattern between primary tumor and metastases.
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Chapter Two: Breast Cancer
2.1 Biology of Breast Cancer
Breast cancer is the most common form of cancer in women, affecting one in every eight
women in the United States [1]. Normal breast has six to nine overlapping sections, called lobes.
Within each lobe there are many smaller lobules, which end in dozens of tiny bulbs that can
produce milk. The lobes, lobules and bulbs are all linked by thin tubes called ducts. These ducts
lead to the nipple in the center of a dark area of skin called the areola (figure 1). Fat fills the
spaces around the lobules and ducts. There are no muscles in the breast, but muscles lie under
each breast and cover the ribs. Each breast also contains blood and lymph vessels. The lymph
vessels lead to small bean-shaped structures called lymph nodes. Clusters of lymph nodes are
found in the axilla (under the arm), above the collarbone and in the chest [2].

Figure 1 normal anatomy of the breast. Shows the normal structure of lobes, lobules and ducts.
Lymph nodes are shown in the axilla region. Adopted from [2]

Normal breast growth and development are regulated by the complex interaction of many
hormones and growth factors include estrogens, progesterone, androgens, glucocorticoids,
prolactin, thyroid hormone, insulin and insulin-like growth factors (IGF-1 and IGF-2), fibroblast
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growth factors (FGF), and epidermal growth factor (EGF)/transforming growth factor alpha
(TGF-α) [3]. The interaction of growth factors, cytokines, and hormones with specific membrane
receptors triggers a cascade of intracellular biochemical signals, resulting in the activation and
repression of various subsets of genes. Several of these hormones have been shown to play an
active role in the development of breast cancer. For example, estrogen stimulates breast cell
division, which can increase the risk of breast cancer. Furthermore, breast cells are not fully
mature in girls and young women who have not had their first full-term pregnancy [2]. Breast
cells which are not fully mature bind carcinogens more strongly and they are not as efficient at
repair DNA damage as mature breast cells. Breast cancer, like any other cancer, takes years to
develop, and it can take place at any part of the breast anatomy. In terms of histology, breast
cancers are heterogeneous, they are mainly ductal, but also lobular, mixed ductal and lobular,
cribriform, mucinous and tubular carcinomas [4]. Figure 2 illustrates the stages of breast cancer
development at the ductal part. For some reason mostly DNA mutations in any of breast genes,
normal cells divide rapidly and causes ductal hyperplasia, which with time develop to atypical
ductal hyperplasia then ductal carcinoma in situ (DCIS) and in then becomes DCIS with
microinvasion (DCIS-MI).
2.2. Subtypes of breast cancer
Based on the hormones and growth factor regulations, breast cancer has several subtypes, the
most commons are:

Basal (Triple Negative) Breast Cancer
The basal subtype is also called “triple negative” cancer, because the cells are negative for three
common markers: estrogen receptors (ER), progestin receptors (PR), and human epidermal
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growth factor receptor-2 (HER-2). Although the basal subtype is only found in about 15% of
breast cancers, it has been shown to be aggressive, unresponsive to treatment and, ultimately,
indicative of a poor prognosis [5]. Basal-type breast cancer is diagnosed more often in African
American women than in Caucasian women in the United States [6]. Compared to other subtypes,
it is poorly defined by mammography and best detected by MRI. It is also often detected as grade
III, tumors, resulting in more aggressive and poor overall prognosis [7].
HER-2 Over-expression Breast Cancer
As the name suggests, HER-2 over-expressing tumors have extra copies of the HER-2 gene and
over-produce the resulting growth-enhancing protein. This protein is overexpressed in about 20%
of breast cancers [8]. Biologically, the up-regulation of HER2 gene is associated with increased
proliferation, angiogenesis, and invasiveness [9].
These tumors tend to grow quickly but are responsive to targeted drug treatment with compounds
like, Trastuzumab and more recently other drugs such Lapatinib and Pertuzumab

which have

shown specific activity against HER2 positive breast cancer and an increase in the median
survival up to 2 years [10].
Luminal A and B Breast Cancers
Luminal A and B subtypes are both estrogen-receptor-positive (ER+) and low-grade, with luminal
A tumors growing very slowly and luminal B tumors growing more quickly. Luminal A tumors
have the best prognosis. Several studies have been conducted using microarray technology, to
study breast cancer subtypes showed that, for different gene expression profiles, prognosis and
treatment response vary for different subtypes [11]. Luminal B compared to luminal A shows
lower expression levels of ER or estrogen-regulated genes, lower or no progesterone receptor
(PR) expression, higher tumor grade, higher expression of proliferation-related genes and
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activation of growth factor receptor signaling pathways. Also luminal B tumors have lower
sensitivity to endocrine treatment and higher sensitivity to chemotherapy than luminal A tumors
[12].

Figure 2 breast cancer (DCIS-MI) developments. Ductal hyperplasia develops to Atypical ductal
hyperplasia then ductal carcinoma in situ. With microinnovation at late stages become ductal
carcinoma in situ with microinvasion (DCIS-MI).adopted from [2]

2.3. Treatment of breast cancer
Treatment options of breast cancer include; surgery, chemotherapy, radiotherapy, hormone
therapy and immunotherapy. The choice of treatment is based on the tumor subtype and stage of
the disease. Several studies showed that, combination of treatment options (adjuvant therapy) is
more effective than single agent therapy. Radical mastectomy (local surgery) followed by
radiotherapy produce local control. Chemotherapy is preferred in cases of receptor-negative
tumors, acquired resistance to hormonal therapy and aggressive visceral metastatic diseases.
Primary chemotherapy is increasingly used in the treatment of locally advanced tumors with
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increased rates of breast-conservative surgery. In case of hormone receptor positively and absent
of visceral, life-threading disease, endocrine manipulation is the treatment of choice [13].
Endocrine manipulation usually done, using Tamoxifen or ovarian ablation or both (both are more
effective), for postmenopausal patients [13]. Immunotherapy of breast cancer as an adjuvant
therapy, based on active immunizations or passive therapy has in some instances been shown to
prevent tumor recurrence and improve patient survival [14]. The rationale behind immunotherapy
for breast cancer can be highlighted in two points: i) Breast screening provides an opportunity to
employ immunotherapy in early stage of tumor development, when the immunosuppressive
effects of the tumor are relatively low, ii) Breast cancer expresses specific tumor antigens which
can be utilized to ex vivo engineer T-lymphocytes to yield tumor specificity [15].

2.4. Adoptive Immune cell Therapy (AIT)
The first observations that the immune system has antitumor effects against sarcoma tumors
were noticed in 1890s by William Coley [16]. After years later, researchers noticed that, the major
mediators inducing this effect are T cells [17] and based on this rationale the concept of Adoptive
cellular immunotherapy (ACI) or Adoptive cell transfer (ACT) or Adoptive immune cell therapy
(AIT) was introduced [18]. The immune response to genetic changes in transformed tumor cells
appears from the accumulation of antigen-specific T cells within the tumor and draining lymph
nodes [19]. T-cells function as part of the adaptive immune system, to attack and kill tumor cells;
unfortunately tumors keep growing because the anti-tumor immune response is either not
sufficiently strong to eliminate tumor cells or the anti-tumor immunity is suppressed by regulatory
cells or other factors secreted by the tumor. In the past, the immune system has been thought to
play a role in the recognition and elimination of nascent malignancies through so called
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immunosurveillance [20]. However, because of a lack of concrete evidence, the hypothesis of
immunosurveillance had been abandoned and recently a new concept called immunoediting
which is comprised of three phases; elimination, equilibrium and escape phase, has been
demonstrated:
1. Elimination phase: during the elimination phase, T cells (CD4, CD8, NK and γð cells)
appear to recognize transformed cells early in the development of tumors; the mechanism
of this recognition is not fully understood but sufficient to kill some tumors.
2. Equilibrium phase: in the equilibrium phase, tumors that are not completely eliminated
undergo a selection process termed immunoediting whereby tumor cells “ hide” their
antigens by weak expression or endocytosis, thereby allowing tumor cells to escape
immune response, survive and accumulate mutations.
3. Escape phase: in the escape phase, when tumors are fully developed and can be detected,
they can promote immune suppression through recruitment of suppressive cells such as
regulatoray T cells (T-reg) and production of suppressive cytokines as IL-10 and TGFß
[21- 23].
AIT could overcome the limitations described above, because it relies on enhancing the
patient’s immune system ex vivo isolated from the suppressive environment of tumor cells. It is
based on isolation, expansion, and re-infusion of large numbers of tumor specific patient’s own
immune cells, particularly cytotoxic T lymphocytes, to induce tumor regression. Potentially, AIT
could be an effective treatment strategy, because it facilitates direct interaction between immune
cells and tumor cells without adverse effects on normal cells.
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In order to understand the dynamics and the process of AIT and to monitor the migration,
localization and retention of labeled immune cells, in vivo studies, in live subjects and within
the intact physiological environment, are needed.

2.5. Adoptive Immune Cell Therapy (AIT) of breast cancer
Breast cancer is a systemic disease with primary local tumor and disseminated metastatic
disease. The aim of Surgery, chemotherapy and radiotherapy is to induce primary tumor
regression over the specific treatment regimen. Clinically in breast cancer, micrometastatic tumor
can be eliminated using hormone therapy, chemotherapy and AIT [24]. In wide variety of breast
cancer, the tumor-infiltrating T lymphocytes, particularly type-1 helper T cells (Th1) and
cytotoxic T lymphocytes cells (CTL) are correlated with the absence of metastatic invasion and
increased overall survival rates [25]
Several studies in AIT of breast cancer highlighted that, the success of AIT is based on the
ex vivo activation of T cells. It occurs through two stages: an ex vivo stage involves incubating Tlymphocytes with appropriate antigens or non-specific activators (either antibodies or chemicals)
and growth factors that mimic the in vivo activation environment. One such environment has been
achieved by pulsing T-lymphocytes in Bryostatin 1 and Ionomycin, which mimic TCR signaling
to trigger the T-cell activation pathway. Bryostatin 1 activates Protein kinase C (PKC) and
Ionomycin increases intracellular calcium, and together they lead to activation of transcription
factors: nuclear factor Kβ (NF Kβ) and nuclear factor of activated T cells (NFAT) respectively.
These transcription factors move to the nucleus and initiate the transcription of IL-2 and other
genes which are essential for T-cell proliferation [26-28]. The in vivo stage through the interaction

32

between MHC–peptide (Major Histocompatibility Complex) expressed on antigen- presenting
cells e.g. dendritic cells (DCs) to initiate T-cell activation [28].
The success of AIT relies on manipulation of tumor specific T-lymphocytes to produce
large numbers of these cells as well as optimization of effector functions. AIT allows the
generation and activation of T-lymphocytes away from the suppressive tumor environment
providing the optimal environment for anti-tumor responses [29]. One example of AIT success in
the treatment of advanced metastasized breast cancer patients was shown by Christoph Domschke
and his colleagues [30]. They demonstrated that, adoptively transferred T-cell clones (tumor
antigen-reactive type-1 T cells) persist in vivo and preferentially localize to tumor sites and
mediate an antigen-specific immune response characterized by metastases regression and
significantly longer overall survival in 7 of 16 patients. Another study showed that the re-infusion
of T lymphocytes, engineered to express Tumor- specific TCR, induce regression in 13% of
patients [31]. The question is; why some patients respond to the therapy and some do not?
Tracking the movement, proliferation and viability of re-infused tumor specific T-lymphocytes by
multi-modality imaging in serial images at different time points during the treatment could define
the parameters that lead to successful AIT. Therefore, In order to understand the dynamics and the
process of AIT, noninvasive and repetitive multimodality imaging of

labeled immune cells

provides the opportunity to study in vivo trafficking, homing, tumor targeting, activation,
proliferation and persistence of transferred labeled cells [32].
This thesis aims to contribute new knowledge in this context, by direct in vivo imaging
of pathways associated with the process of AIT.
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Chapter Three: Molecular Imaging of AIT
3.1. Introduction
Molecular imaging is the visualization, characterization, and measurement of biological
processes at the molecular and cellular levels in humans and other living systems [33]. The main
advantage of in vivo molecular imaging is its ability to characterize diseased tissues without
invasive biopsies or surgical procedures and with this information in hand; more personalized
treatment planning can be applied [34]. Different imaging modalities are used for molecular
imaging, including optical (fluorescence and bioluminescence), positron emission tomography
(PET), single photon emission computed tomography (SPECT), magnetic resonance imaging
(MRI) [35] and more recently the development of Multi Spectral Optoacoustic Tomography
(MSOT) imaging [36]. Optical imaging utilizes light photons at different wavelengths at visible
and infrared ranges resulting from fluorescent and biolumencent events. The application of optical
imaging is limited in humans because the wavelength of the probes emitted in the biolumencent
or fluorescent processes are too weak to penetrate deep and thick layers of tissues that are bloodrich tissues. In optical imaging, low noise images require acquisition times of about 5-10 minutes,
which may increase the thermal noise, but this can be reduced with thermo-electric cooler.
However, this technique is widely used in molecular imaging due to its simplicity and cost
effectiveness [37]. Radionuclide-based imaging methods (PET and SPECT) are based on gamma
(γ)-positron and single photon emitting radionuclides used to radiolabel probes specific for the
process under study. Clinical PET has spatial resolution of about 5mm, while animal micro-PET
resolution is about 1.5 mm [38]. PET compared to SPECT has higher sensitivity and both are
independent of tissue depth.
MRI is widely used for soft tissue imaging. The physics of MRI is based on the alignment
of the protons to magnetic field (MF) when they are placed in strong MF and form longitudinal
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magnetization. Radio frequency (RF) pulses are used to alter the protons alignment and tilts the
longitudinal magnetization to be transversal magnetization , when the RF is turned off, the
protons realign with magnetic field again and generate an electromagnetic flux that provide
information about tissues under study. Due to this, the image acquisition time is long but high
spatial resolution and good image contrast is achievable [39].
Table-1 summarizes the advantages and limitations for each imaging modality and their
application in cell-based imaging and trafficking. The role of molecular imaging in AIT is to
optimize and maximize the chance of AIT success for each individual patient as the cells are the
patient’s own cells [40]. A number of variables need to be optimized for each individual patient to
obtain the desired outcome of AIT. As an example of these variables, is the number of cells to
effectively treat a certain tumor. Measuring tumor size and injecting different numbers of cells
will provide information about the effective number that has to be injected for each individual
patient.
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Table: 1 demonstrated some characteristics of each modality regarding to their use in cell therapy
monitoring and imaging.
Modality

PET

SPECT

Imaging probe
Used to track
cells
18
F-FDG,
18
F- FHBG
18
F-FEAU,
124
I-FIAU
64
Cu-PTSM
89
Zr- Oxine

111

In-Oxine,
Tc-HMPAO,
123/125/131
I- FIAU
99m

MRI

Optical
Imaging

Iron oxide
nanoparticles
(SPIO),
Gadoliniumchelates

Organic dyes,
fluorescent
proteins,
quantum dots
and luciferase in
bioluminescence
imaging

Advantages

Limitations

Unlimited depth
penetration,
Whole-body imaging,
quantitative data,
anatomical and
physiological
information when
combined with CT

Radiation exposure
Expensive, long
acquisition time (minutes
to hours), low spatial
resolution when used
alone

Unlimited depth
penetration,
Whole-body imaging,
quantitative data,
anatomical and
physiological
information when
combined with CT
High spatial resolution,
Unlimited depth
penetration, no ionizing
radiation,
Whole-body imaging,
Excellent soft-tissue
contrast
Fast,
simple ,inexpensive,
quantitative, high
sensitivity, and no
ionizing radiation

Quantitative, unlimited
depth penetration, Low
spatial resolution and
ionizing radiation.

Application in
AIT

Has been used
to label
directly or
indirectly
T cells, DC
and other
immune cells
for monitoring

Expensive,
Limited sensitivity
(require large amount of
the probe which might be
toxic to the subject under
study) and long
acquisition time
Limited depth penetration
(≤ 1cm)

cell
localization
trafficking
And
persistence
in vivo in
animals and
human.

[18F]-FDG =[ 18F] fluoro-2-deoxy-d-glucose, [ 18F]-FHBG= [ 4-18F- fluoro-3- (hydroxymethyl)
butyl] guanine, 18F-FEAU= 2’- 18F- fluoro-2’-deoxy-1-beta-d-arabinofuranosyl-5-ethyluracil, 124IFIAU = 2’-fluoro-2’- deoxy- 1-beta-D-arabinofuranosyl-5- 124I- iodouracil, 64Cu-PTSM= 64Cu99m
99m
pyruvaldehyde-bis
(N4methylthiosemicarbazone),
Tc-HMPAO=
Tchexamethylpropyleneamine oxin
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3.2. Labeling approaches
Molecular imaging of immune cells requires labeling of these cells directly or indirectly.
Direct labeling is based on the incubation of activated and in vitro expanded immune cells in the
labeling probe for a few minutes (10-30 minutes) followed by washing then reinfusion into a
subject under examination, followed by serial images at different time points. This method
depends on the ability of a cell to retain the label. The advantages of direct labeling approach are
relatively easy, low expenses, and well established methods. However, this method does not allow
Long term monitoring of labeled cells because the label is lost or diluted as a result of apoptosis
or mitosis respectively [41,42].
Indirect labeling is achieved through transduction of immune cells with a reporter gene,
for example; Herpes Simplex Virus type 1-thymidine kinase (HSV-1 tk, cell cytoplasm labeling).
The product of this reporter gene is an enzyme that phosphorylates a radio-labeled substrate 2fluoro-2-deoxy-1 β- D- arabinofuranosyl-5-

124

I iodouracil [

124

I ]-FIAU for PET imaging.

Figure 3 demonstrates the strategies of direct and indirect labeling approaches. Figure 4 showed
schematic representation of the indirect labeling mechanism and trapping of the labeled probe by
the cell.
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Direct Labeling method

Indirect Labeling method

Figure 3 direct and indirect labeling strategies. Direct labeling (1- immune cells harvested from
donor animal and ex vivo activated and expanded, 2- cells labeled with radio or optical probe, 3cell reinfused to same strain host animal bearing same tumor, 4- serial imaging over specific
period of time preformed). Indirect labeling (1- immune cells harvested from donor animal and ex
vivo activated and expanded, 2- cells transduced with reporter gene (RG) using viral vector
carrying RG, waiting few days for gene expression and RG enzyme production, 3- transduced
cells reinfused to same strain host animal bearing same tumor, 4- a substrate of the RG enzyme
injected and serial imaging over specific period of time preformed) [43].
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Gene delivery
by viral vector

Figure 4 the indirect labeling method from cell transduction to imaging. Viral vectors are used to
transduce cells with specific reporter gene (RG), once the transduction is established and the RG
is integrated into cell genome, transcription and translation controlled by specific promoter occur.
The product of RG translation is an enzyme which will phosphorylate specific probe to be trapped
in the transduced cells [44].

Indirect labeling method allows for reliable, stable and harmless visualization of cellular
trafficking, persistence, proliferation and function at target site. Furthermore, it permits long-term
cell monitoring (months) if the RG is integrated into target cell genome [45]. However, this
approach is limited by targeting or delivery of the RG to cell under transduction, integration,
activation, amount or level of RG (transduction efficiency), RG expression and persistence over
time and immune response problems.
A number of RGs have been developed for radio and non radiotracer (Bioluminescence) imaging,
(listed in table 2). Three categories are identified based on the RG product: transporter, enzyme
and receptor.

The transporter group includes the sodium iodide symporter (NIS) and the

norepinephrine transporter (NET). The enzyme classification includes herpes simplex virus 1
thymidine kinase (HSV1-tk) gene and the HSV1-tk mutant (HSV1-sr39tk). The receptor group
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includes Specific membrane receptors (SSTrs), which mediate the various actions of somatostatin,
which is a peptide that inhibits the release of growth hormone. RG applications initially were in
gene therapy and adoptive cell-based therapies. Recently, noninvasive in vivo reporter gene
imaging is likely to include: (a) quantitative monitoring of gene therapy vectors for targeting and
transduction efficacy in clinical protocols by imaging the location, extent and duration of
transgene expression; (b) monitoring of cell trafficking, targeting, replication and activation in
adoptive T-cell and stem/progenitor cell therapies; and (c) assessments of endogenous molecular
events using different inducible reporter gene imaging systems [46].

Table 2 RGs classifications based on their products and their corresponding probes [46].
Class

RG

RG probe (RGP)

Imaging modality

SSTr2

[ 111In] DTPA-Octerotide
[ 99mTc ] P829
[ 99mTc ] P2045

SPECT

NIS

[ 99mTc ] Demotate1
[ 124I] Iodine

NET

[ 99mTc ] Pertechnetate
[ 131I] Iodine
[ 123I] MIBG

Receptor

Transporter

SPECT
PET
SPECT
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[123,124,125,131I ]-FIAU
[18F ]-FIAU
[123,124,125,131I ]-IVDU
[123,124,125,131I ]-VFAU
[123,124,125,131I ]-IVFRU
[18F ]-FEAU
[18F ]-FHBG
[18F ]-FHPG
[18F ]-FIRU
[18F ]-FUdR

HSV1tk
HSV1-sr39tk

Enzyme

Firefly luciferase
Renilla Luciferase

luciferin
coelenterazine

PET and SPECT
PET
PET and SPECT
PET and SPECT
PET
PET
PET
PET
Bioluminescence
Bioluminescence

3.3. PET imaging
3.3.1. Decay and annihilation
PET imaging was developed several decades ago. Currently, it is playing an important role in
the diagnosis, staging and therapy monitoring of different types of cancer [47]. PET probes or
tracers are radiopharmaceutical compounds labeled with a positron-emitting radionuclide. The
most widely used PET tracer is the fluorinated analogue of glucose fluorodeoxyglucose (FDG)
labeled with

18

F due to the increased utilization of glucose by brain and heart normal cells and

also malignant cells. Positron emitting radionuclides are neutron- deficient isotopes which reach
stability through nuclear transformation of proton to neutron (figure 5a) with emission of positron
(positive electron e+ ) and neutrino. The maximum energy of emitted positron depends on the
isotope, it ranges from 0.6 MeV of

18

F to 3.4 MeV of

82

Rb [51]. The emitted positron travels a

certain range depending on its energy, which will be lost through interactions with surrounding
tissues until it annihilates with an electron (figure 5b). The result is 2 annihilation gamma rays,
0.511 MeV energy each emitted in opposite directions (about 1800 from each other) and detected
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in coincidence within time window of 2τ ns. The distance traveled by the positron from the decay
event to the annihilation event (positron range) and the non-linearity of the annihilation gamma
rays cause loss of spatial resolution that cannot be recovered during image reconstruction.
3.3.2. Coincidence events
Three coincidence events in PET are identified as: true, scattered, and random (figure 6). True
coincidence occurs when both photons from an annihilation event are detected by detectors in
coincidences and no other event is detected within the time window. A scattered coincidence
occurs when at least one of the detected photons undergoes Compton scattering prior to detection.
Scattered coincidences add background to the true coincidence, decreases image contrast and
cause overestimating of the isotope concentration. Random coincidences occur when two photons
are not arising from the same annihilation event and detected within the convenience time
window [48].

42

0.511 MeV

(b)

1800

(a)

0.511 MeV

Figure 5 demonstrations of the positron emission and annihilation. 5a An unstable nuclide
with an extra proton which decays into neutron, positron and neutrino. 5b positron travels
a certain distance depends on its energy then annihilates with an electron and the result 2
gamma rays (511Kev each) emitted in opposite direction about 1800 away from each
other.

A

True Coincidence

B

Scattered coincidence

C

Random coincidence

Figure 6 A true coincidence detection occurs when the two gamma rays are detected from one
annihilation event in the time window. B if at least one of the gamma photons under goes
Compton scattering, and both photons still detected in the time window, scattered coincidence has
occurred. C random coincidence occurs when both photons detect in the time window and are
from deferent annihilation events.
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3.3.3 PET Radionuclides used for imaging in AIT
Avariety of radionuclides has been used to track and monitor labeled cells in vivo. The common
radionuclides are listed in table 3.

18

F is widely used as PET radionuclide in many applications

due to its short half-life and fast clearance from subject under study. However, it requires rapid
radiochemistry and immediate delivery.

64

Cu and

124

I have relatively longer half-lives making

them more acceptable for long term tracking and monitoring of labeled cells.
Table 3 Isotopes and examples of their radiotracers used to track immune cells for PET imaging.
Nuclide &
Mechanism of cell labeling
Half-life Decay modes
Maximum
production
Radiotracer
positron
energy (MeV)
and yield (%)
18
+
18
F-FDG
Cross cell membrane by
109.8
EC, ß
0.634
O (p ,n) 18F
20
transporters
minutes
(96.7 %)
Ne (d, α) 18F
64
+
62
Cu-PTSM Lipophilic cross cell
12.7
EC, ß , ß
0.653 (17.4%)
Ni (p, n) 64Cu
membrane through passive
diffusion
hours
124

89

I- FIAU

Zr-Oxine

Trapped by cell through
phosphorylation by viral
thymidine kinase produced
by transduced cells
Lipophilic cross cell
membrane through passive
diffusion

4.18 days

EC, ß+

3.26 days

ß+

2.138 (23.0%)

126

1.74 (12%)

89

Te (p,3n) 124I

Y(p, n) 89Zr

3.4. Optical Imaging
3.4.1. Introduction
Optical imaging is noninvasive in vivo imaging with light photons detected by charged
coupled device (CCD) detectors made from silicon crystals which have high sensitivity to light.
Two common types of optical imaging are well-known in the realm of molecular imaging;
fluorescence and bioluminescence imaging. In the Fluorescence imaging an excitation light of one
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wavelength in the range between 395-600 nm illuminates the subject under study and an emission
light with wavelength higher than the excitation wavelength detected by CCD detector [49]. The
use of near-infrared probes (spectrum range 700-1000nm) for optical imaging maximizes tissue
penetration because hemoglobin and water which are the major absorbers of light have lowest
absorption coefficients in the infrared range. In bioluminescence imaging only the emission light
is detected by CCD detectors and no excitation light is used in this technique. The most
commonly used bioluminescence probes are reporter genes, Firefly or Renilla Luciferase ( FLuc
or RLuc respectively). Their substrates are Luciferin for FLuc and Coelenterazin for RLuc. In
case of using FLuc, cells transfected by FLuc gene and express the Luciferase enzyme that will
oxidize the Luciferin ( given as i.v. injection at different time points) in the presence of oxygen,
ATP and magnesium (Mg2+) to produce Oxyluciferin and light which will be detected by CCD
camera to be quantified and process image reconstruction. The main advantage of
bioluminescence imaging is that it can detect very low signal and the background signal is very
low. But the efficiency of the transmission light is limited and depends on the tissue type. Skin
and muscle have highest transmission, whereas highly vascular organs such as liver and spleen
have lowest transmission because of the absorption of the light by oxyhemoglobin and
deoxyhemoglobin [50 ].
3.4.2 Multi-spectral fluorescence imaging (theory and concepts)
3.4.2.1. Florescence (definition, emission and excitation spectrum)
Fluorescence is the emission of light that occurs rapidly (around one million of a second)
after illumination. When the light emission takes longer time is called phosphorescence. Two
major problems are encountered with fluorescence measurement: first, fluorescence is emitted by
the fluorescent molecule such as dyes in all directions and most imaging systems are designed to
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capture light coming from particular direction. Second, it is difficult to obtain identical excitation
of the total fluorescent molecules in the subject under study [51]. Fluorescent materials always
emitted light with longer wavelength than the exciting light. The differences between wavelengths
of emission and excitation lights is called Stoke’s shift. The range of the excitation wavelengths
known as absorption spectrum, while the emitted light covers range of wavelengths known as
emission spectrum. In most cases there is overlap between the excitation and the emission
spectrum.
3.4.2.2. Autofluorescence (definition and multispectral analysis solution)
Some biological materials such as vitamins, hormones, and enzymes are naturally
fluorescent. Resulting strong fluorescent signals interfere with the signal of specific labeling
probe and cause unwanted background which known as autofluorescence. Animal skin, fur and
food, particularly if the food contained Chlorophyll, are strong sources of the autofluorescence
signals [52]. Excitation and emission filters are used to reduce this problem. Both filters should be
chosen to match the maximum excitation and emission wavelengths of a specific probe.
Multispectral imaging systems provide a unique solution to the autofluorescence problem using
multispectral analysis. It is based on the fact that all fluorescent materials produce specific
emission spectra. Multispectral analysis generates spectral curves for the various fluorescent
materials and autofluorscence curves in the subject under study. Based on this technique a series
of images are captured called image cube taken at specific wavelength. Using sophisticated
algorithms, the contribution of autoflourscence to the image can be removed, and specific
fluorescence spectra for specific probe are separated.
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3.4.2.3. Multi-spectral imaging system (Maestro2)
The multi-spectral imaging system used in
this project is shown in figure 7. The various
components of the system

include, high-

resolution, scientific- grade CCD imaging
sensor,

solid-state

wavelength

tuning

liquid

crystal

element,

(LC)

spectrally

optimized lens and internal optics, an
excitation light source and emission filter
assembly.

The system has a control panel

with switches for the excitation lamp, shutter,
and white interior lights. It also displays the
system statues such as the interior temperature
and current filter wavelength.

Figure 7 Multispectral fluorescence imaging system (Maestro2 at CMI/VCU). Wavelength range =
500-950 nm; FOV = Max 3 mice; Spectral Unmixing and Dynamic Contrast Enhancement (DyCE™)
allows quantitation of temporal biodistribution of fluorescent markers at much earlier time points (first
few seconds following injection).
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3.5. Labeling and imaging of T lymphocytes (literature review)
Noninvasive in vivo imaging of adoptively transferred T-lymphocytes requires an
effective and mild labeling methodology and the right imaging technology direct labeling enables
the imaging of cells labeled ex vivo and reinfused into the patient or subject who is being
examined. Radionuclide based direct labeling probes for SPECT/PET imaging includes include,
[111In]-Oxine, [18F-]FDG,[99mTc]-HMPAO, and[64Cu]-PTSM. These have been used to monitor
the migration of T-lymphocytes in vivo [53, 54]. However, these techniques do not permit long
term monitoring due to the short physical half-life of the radionuclides, relatively low level of
radioactivity per cell, and in certain instances, are limited by significant cell toxicity [55]. On the
other hand, indirect labeling utilizes imageable reporter protein/probe combinations and rely on
the ex vivo transduction of a relevant reporter gene into the immune-competent cells. Following
reinfusion of the transduced cells into the subject, the product of the reporter gene can be imaged
by injecting a suitable radiolabeled substrate. Herpes Simplex Virus Type-1 Thymidine Kinase
(HSV1-tk) is such a PET reporter gene (PRG) and is one of the most commonly used indirect
methods to image adoptively transferred T-lymphocytes in animals and patients, and it can be
imaged with various substrates such as[124I]-FIAU, [131I]-FIAU, [18F]-FEAU and [18F]-FHBG
[58,59]. The sodium iodide symporter (NIS) is another reporter gene that has also been evaluated
for imaging cells of the immune system in immortalized macrophage cell lines genetically
engineered to express NIS and GFP (RAW264.7/hNIS-GFP) [56]. Using [124I-NaI PET imaging,
these investigators monitored macrophage migration towards inflamed tissue. In addition to

124

I,

99m

Tc04, 123I, 125I, [18F]-tetrafluoroborate can also be used as substrates for NIS [57].
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Radionuclide based methods are useful in the clinic due to the ability to image signals
from deep tissues. However, the logistics of radionuclide techniques are more demanding, which
makes them less cost effective for preclinical investigations. Non-radioactive agents, such as
fluorocarbon-based probes, have also been used for efficient direct ex vivo labeling of cells, and
used in conjunction with

19

F MRI for in vivo detection and imaging [58]. This method, which

involves the use of an autologous dendritic cell vaccine to treat colorectal cancer, is currently
being evaluated in humans (personal communication). This represents the first clinical trafficking
study of a live cell cancer vaccine which has been visualized by MRI in the United States.

On the other hand, optical methods are relatively easy, require simpler imaging equipment
and are cost effective, but are not very useful in the clinic due to the lack of effective technology
that can detect optical signals from deep tissues. However, optical labels, both direct and indirect,
could be very useful for research and development of various strategies aimed at improving
immune cell therapy. One cost effective approach is to use optical reporter proteins such as firefly
or renilla luciferase to label the cells and monitor them by optical imaging [59, 60]. However,
these are currently limited to animal models and their success relies on the successful stable
transduction of the reporter gene and the persistence of the reporter gene expression over time. A
combination of direct labeling strategy and optical imaging methodology would be ideal, in terms
of simplicity and cost effectiveness, for monitoring cell trafficking in preclinical studies. This
could be extended to clinical investigations if a suitable imaging component such as

124

I or 19F is

included in the direct cell labeling strategy.
Studies describing optical imaging of directly labeled immune cells is quite limited.
However, using ex vivo imaging and other in vitro protocols, several DNA-binding, cytoplasmic,
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covalent coupling or membrane inserting fluorescent dyes have been investigated for direct
labeling of T lymphocytes to track lymphocyte migration and proliferation [61]. Due to
interference from autofluorescence and tissue absorbance, most of these dyes are not ideal for in
vivo optical imaging and their use is limited to ex vivo detection. The optical imaging window is
primarily limited by absorption, due to either blood at short wavelengths or water at long
wavelengths. This could be overcome with the use of near-infrared dyes (NIR) that will allow
deep tissue signal localization [62]. The red/NIR tissue optical window between 600 and 1300 nm
is the spectral region where light has its maximum depth of penetration in tissues due to minimal
absorption and scattering. Among the various options available for direct labeling, the cell
membrane dyes retain the signal for relatively longer periods than DNA-binding, cytoplasmic or
covalent coupling dyes [63]. Therefore, a combination of NIR based fluorescent cell membrane
dyes would offer a direct labeling method for monitoring cell trafficking while exploiting high
sensitivity, simple labeling technique, decreased autofluorescence and relatively low costs.
In this project multi-spectral fluorescent imaging was extensively used to investigate the
in vivo kinetics of labeled T-lymphocytes. In addition, the feasibility of indirect reporter gene
imaging, using the (HSV1tk / [

124

I ] FIAU system) was also examined for PET imaging

approach.
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Chapter Four: Materials and Methods
The following diagram is a summary of the project strategy, details are provided on the following
pages.

Harvesting,
activating and ex
vivo expansion of
T-lymphocytes

Ex vivo
growing 4T1
Breast
carcinoma
tumor cells

Direct labeling of
expanded T-cells
using NIR
fluorescent probe
for optical imaging

Indirect labeling using
reporter gene HSV
1tk- 124I-FIAU for
PET imaging
Synthesis of
radiolabeled
[124I]-FIAU

In vitro evaluation of
the labeling effect on
cell proliferation,
function, and viability

Multi-Spectral
Fluorescent imaging at
different time points
Post-administration of
labeled cells

Transient transfection for
optimization.
Then stable transduction
using lentiviral method

In vitro detection
of reporter gene
expression

In vitro evaluation of
[124I]-FIAU accumulation
in the labeled cells

PET imaging and
biodistribution study
at various time points
Post-administration of
labeled cells
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4.1. Animals
Female BALB/c mice, aged between 8-12 weeks, obtained from National Cancer Institute,
Bethesda, MD, were caged in groups of five or fewer, and provided with food and water ad
libitum. All animal experiments were performed according to the policies and guidelines of the
Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University,
USA.

4.2. Cell lines
Murine mammary breast carcinoma (4T1) cell line was kindly provided by Dr. Jane Tsai,
Michigan Cancer Foundation, Detroit, Michigan. 4T1 cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal calf serum (Hyclone, Logan,
UT) 1 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma, St. Louis MO)
and 10 mM HEPES (Thermo Scientific). Tumor cells were trypsinized with 0.05% trypsin-EDTA
(Fisher, Pittsburgh), washed with PBS and used for experiments.
Meth-A sarcoma cells were obtained from American Type Culture Collection (Rockville, MD)
and grown in DMEM media, containing 10% heat inactivated fetal bovine serum, 1 mM sodium
pyruvate, 100 u/ml pen/strep, 10 mM HEPES, and 2 mM L-glutamine in incubator with 5% CO2,
at 37° C. Cells > 90% confluence were trypsinized and used for experiments.
Jurkat cell line was obtained from ATCC and grown in RPMI media, containg 10% heat
inactivated fetal bovine serum, 100 u/ml pen/strep and were grown in the incubator with 5%
CO2, at 37° C. cells were counted every other day and kept at a concentration of one million per
ml.
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HEK 293 cell line was obtained from ATCC and grown in EMEM media containg 10% heat
inactivated fetal bovine serum, 100 u/ml pen/strep and in the incubator with 5% CO2, at 37° C.
Cells > 90% confluence were trypsinized and split to be used for experiments.

4.3. Isolation, activation and in vitro expansion of 4T1 tumor specific T lymphocytes
Donor mice were vaccinated in the left hind footpad with viable 1/2 x106 4T1 cells. Ten days
later, when these mice had a growing tumor in the foot, popliteal draining lymph nodes (DLN)
were harvested under sterile conditions and disrupted through mesh screens to yield single cell
suspensions. The cells from DLN were filtered and resuspended in complete RPMI media at
1x106 cell/ml concentration. These cells were then activated by incubating them with 5nM
Bryostatin 1 (Sigma, St. Louis MO), 1µM Ionomycin (Calbiochem, San Diego, CA) and 80 U/ml
IL-2 (Chiron, Emeryville, CA) at 37° C for 18 hours. To expand the lymphocyte population, cells
were washed three times with warm, complete RPMI and resuspended at 1x106 cells/ml
concentration and divided into 2 groups: group-1 was incubated with 40 U/ml of IL-2 (IL2 cells)
and group-2 incubated with IL7+ IL15 (10 ng/ml each) (Chiron, Emeryville, CA) (IL7/15 cells) .
The cells were then allowed to proliferate in culture for 6-13 days and were split every other day
to maintain 1-2x106 cells/ml concentration. Fresh IL-2 or IL-7 +IL-15 was added at each split.
Cell proliferation was calculated by determining the number of viable cells, on every other day of
culture, by trypan blue exclusion and comparing it with the number of cells on day 1 of
expansion. Luminescence based cell viability assays were also carried out as described below.
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4.4. Labeling methods of T- lymphocytes
T lymphocytes were labeled using two approaches: a) direct labeling using NIR fluorescent probe
(DiR dye) for optical imaging, b) indirect labeling using the PET reporter gene (PRG) strategy
(HSV1 tk RG) for PET imaging.

The direct labeling method was used to obtain some

information about the in vivo trafficking of 4T1 sensitized T lymphocytes and to optimize our
experimental model. The indirect labeling method was used to demonstrate its feasibility because
it allows cell monitoring for long periods of time and it can be translated to the clinical setting.

4.4.1 Direct labeling with NIR-fluorescent probe
Direct labeling of T- lymphocytes isolated on day-6 after in vitro expansion was achieved by
incubating the cells with 1,1-dioctadecyltetramethyl indotricarbocyanine Iodide (DiIC18(7) or
DiR), a lipophilic Near-Infra red fluorescent dye (Absorption/ Emission: 748/780nm)
(PerkinElmer, MA). DiR (scheme 1) allows labeling the cell membrane through the insertion of
the long 18-carbon chains into the cell membrane, resulting in specific and stable cell labeling
with negligible dye transfer between cells .DiR stock solution was prepared by dissolving 25mg
dye in 3ml Ethanol. From this stock, further dilutions were made to the required concentrations
in media and incubated with cells for 30 minutes at 37 0C (cells were shaken every 10- minutes).
After incubation, cells were spun down at 1000 rpm at 4° C for 10 minutes, then washed twice
with PBS and used for experiments.
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.
Scheme 1 the chemical structure of the fluorescent probe (DiR)
To examine cell proliferation, viability and function before and after DiR labeling the following
assays were performed:
4.4.1.1. Cell proliferation assessment
Cells were counted every other day using 0.4% Trypan blue (Mediatech VA) and the number of
viable cells was compared to their number immediately after pulsing with B/I. The result of this
comparison is expressed as fold increase. Cell proliferation was assessed based on fold increase in
cell number.
4.4.1.2. Cell Viability assays
The highest tolerable concentration of DiR in the staining solution, which can be used to label Tcells, was determined using Cell Titer-Glo Luminescent assay kit (Promega) and flow cytometry.
Tumor sensitized lymphocytes, cultured in media for 6 days in IL-2 or IL-7+IL-15 containing
media, were labeled with a staining solution containing various concentrations (3.5, 14, 56, 224
and 320 µg/ml) of DiR. Following labeling, 25000 cells/100 µl were plated in triplicates in a 96
well plates, and incubated along with similar number of unlabeled cells in a 37° C CO2 incubator.
After 1, 4 or 7 days of incubation, the Cell Titer Glo reagent was added to the cells and the %
Viability was calculated for each labeled group in comparison to unlabeled cells (100% viability).
For flow cytometry, DiR labeled and unlabeled T-cells (2 or 7 days post labeling) were double
stained with propidium iodide (PI) and AnnexinV-FITC (BD Biosciences Pharmingen, San
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Diego, CA) and analyzed using Beckman Coulter Epics XL-MCL flowcytometer and the data
were analyzed using EXPO 32 software. Two different sets of experiments were performed to
verify the results.
4.4.1.3 Cell function assessment (Interferon- γ release assay)
In vitro: Interferon-γ (IFN-γ) released into supernatants of 4T1 sensitized and expanded Tlymphocytes in response to stimulation with irradiated 4T1 and Meth-A cells (non-specific
control) was assayed using BD OptEIA mouse IFN-γ ELISA kit (BD Biosciences, San Jose, CA).
T-cells obtained from popliteal DLN, which had been activated and expanded in either IL-2 or IL7 and IL-15 containing media, were collected on day 6 and incubated with DiR staining solution
(320 µg/ml) . The DiR labeled and unlabeled cells were collected 1 day and 7 days post-labeling
and incubated with the irradiated 4T1 or Meth-A tumor cells for 24 hrs, and the amount of IFN-γ
in the supernatant was analyzed. As a negative control, 4T1 sensitized T cells alone were
incubated under similar conditions.
In vivo: Blood was collected from three different groups of animals bearing: i) 10 day old 4T1
tumor, ii) 10 day old 4T1 tumor and injected with 10 million labeled T-cells /mouse, iii) 10 day
old Meth-A tumor and injected with similar number of activated and labeled T-cells. One week
later, blood was collected and the amount of interferon-γ in serum was determined using the same
kit and assay described above.
4.4.1.4. Animal model and T lymphocyte trafficking
For the development of tumor models, mice were inoculated subcutaneously into the right flank
with either 4T1 cells or Meth-A tumor cells (5x104) and the tumor was allowed to grow for 3 days
(average tumor volume size 20±5.6 mm3) or 7 days (average tumor volume size 80±10.3 mm3) .
To follow in vivo trafficking of T cells, 4T1 sensitized T-cells were first labeled with DiR
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(320µg/ml staining solution). The cells were then filtered through 70-µm nylon mesh strainer and
injected intravenously (iv) into the mouse tail vein (10x106 cells in 0.5 ml PBS per mouse) either
a week before or after the tumor cells were injected.
To confirm that the detected signal at the tumor site is associated to the DiR labeled viable T
cells, two experiments were performed. First: the DiR at same concentration as used for labeling
was diluted in PBS and injected intravenously into 3 animals bearing 4T1 tumor. After
fluorescent imaging at 2, 24 and 48 hours, animals were dissected and the ex vivo data were
collected. Second: DiR labeled T cells were resuspended in PBS and lysed by freezing and
thawing protocol for 6 times to ensure full cell lysate. Cell viability was tested using Trypan blue
(0.4%). The cell lysate was injected (tail vein i.v. injections) into 6 animals bearing 10 day 4T1
tumors (3 for IL-2 cells and 3 for IL-7/15 cells). Fluorescent imaging was carried out for 2 weeks.
One day before injection of DiR labeled T-lymphocytes, mice were pretreated, intraperitoneally
(ip), with 100mg/kg Cyclophosphamide (CYP) (Mead Johnson, Princeton, NJ).
4.4.1.5. Multi-spectral fluorescence imaging
Fluorescent images were taken from day 1 to day 21 to monitor the homing and localization of
labeled T lymphocytes at the tumor site. Multi-spectral fluorescence imaging system (Maestro-2
by PerkinElmer, USA) was used to monitor DiR labeled T-lymphocyte trafficking and
localization in host mice with and without tumors. A NIR/Orange double filter setup (640nm to
820nm) and spectral unmixing was used for image acquisition and processing. Image processing
and data analysis were performed using Maestro-2 software version 2.10. Images were obtained
at different time points ( 2 hours, 24 hours, 48 hours, 72 hours, 6-days , 8-days, 10-days, 13-days,
15-days, 17-days, 20-days, and 21-days ) post-injection of labeled T-lymphocytes. Six mice per

57

time point were used; and four imaging positions, Dorsal, Ventral, Left and Right sides, were
used at each time point.
4.4.1.6. Immunohistochemistry analysis
After imaging, mice were euthanized, organs and tumors were collected, embedded with Optimal
Cutting Temperature compound (O.C.T, Tissue-Tek, USA) and stored at -80° C. Using a cryostat
system (LEICA CM1850 UV), five-micron thick serial sections of the samples were collected
onto glass slides. The sections were fixed for 15 min in 3% freshly prepared paraformaldehyde in
PBS (pH 7.4) at room temperature, and then washed three times with 0.3M glycine in PBS.
Antigen retrieval was done using heat and citric acid buffer method. Following this, sections were
washed three times in PBS for 5 min each, then incubated with blocking buffer ( 5% normal goat
serum + 0.1% Triton X-100 in PBS, pH 7.4) for 1 hour at room temperature. Tissue sections were
incubated overnight, at 4°C with Anti-F4/80 and Anti-CD69 primary antibodies (Abcam, USA).
This was followed by incubation, for 1hr at room temperature, with Alexa Fluor 488 goat anti-rat
IgG and Alexa Fluor 568 Goat anti-hamster IgG (Abcam, USA), which were used to detect
macrophages and activated T cells respectively. The sections were cover-slipped with Vectashield
Mounting Medium (Vector Laboratories, Burlingame, CA), and were then imaged and analyzed
using Zeiss LSM 700 confocal laser scanning microscope.
4.4.2. Indirect labeling method using PET Reporter Gene (PRG)
The second method was the indirect labeling of T- lymphocytes through transduction of reporter
gene (cell cytoplasm labeling Herpes Simplex Virus type 1- thymidine kinase (HSV-1 tk). The
product of this reporter gene is an enzyme that phosphorylates a radio labeled substrate 2-fluoro2-deoxy-1 β- D- arabinofuranosyl-5-

124

I iodouracil [

124

I ] FIAU for PET imaging. Before we

established this method, we performed transient transfection using transfection reagents to
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transfect Jurkat cells (these cells are T cells derived from a subject who had lymphoma; they are
similar in their features to T cells and produce IL-2). The transient transfection method, as
described below, was done to optimize our detection method (western blot) of the HSV1 tk
expression.
4.4.2.1. Transient transfection
4.4.2.1.1. HSV1tk vector isolation:
An expression vector containing the HSV-1 tk fusion gene (pORF9-HSV-1tk: Sh ble)
(Invitrogen) was transformed to E.coli bacteria strain GT116. The E coli bacteria was grown by
streaking of 50µl of the E coli stock on LB agar plates and incubated for 24 hours at 37 0C. One
single colony was picked up and grown in 10 ml of the LB media overnight at 37 0C. Then the 10
ml Ecoli grown media was added to 150 ml of the LB media to grow overnight at 37 0C. The 150
ml volume of the Ecoli grown media was enough to isolate good concentration of the plasmid
vector.

The plasmid vector was isolated by Gen Elute HP- plasmid maxiprep kit ( Sigma-

Alridsh) following the kit protocol. The HSV1tk plasmid (DNA) concentration and purity was
measured as following:
The HSV1-tk plasmid concentration was calculated using the following formula:
Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50µg/ml
A260 and A320 are the DNA and RNA absorbance respectively, measured by spectrophotometer,
dilution factor = 100, the formula multiplied by 50µg/ml because as role of thumb OD of 1 =
50µg/ml.
Total yield is obtained by multiplying the DNA concentration by the final total purified sample
volume.
DNA yield (µg) = DNA concentration × total sample volume (ml)
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DNA purity was calculated using the following formula:
DNA purity (A260/A280) = (A260 reading – A320 reading) ÷ (A280 reading – A320 reading)
A280 = other contaminants absorbance.
Good-quality DNA will have an A260/A280 ratio of 1.7–2.0. In our experiments we frequently have
obtained DNA concentration between 500 to 700 µg/ml and DNA ratio of 1.7 -1.8.
4.4.2.1.2. Confirmation of the presence of HSV1-tk gene in the isolated vector
Using restriction enzymes (NcoI-HF and NheI-HF) (Invitrogen) to perform single and double cut
of the HSV1-tk plasmid and perform gel electrophoresis to determine the plasmid size and
confirm the presence of HSV1tk gene. The DNA resulted from maxiprep was heated at 750 C for
10 minutes to inactivate DNase. Then 5 samples were prepared: sample 1 and sample 5 is 2ul 1Kb
DNA ladder + 2ul gel loading dye to help as guide to calculated DNA size. Sample 2 is 2.5ul
intact plasmid DNA + 2ul gel loading dye, sample 3 is single cut of DNA by Nco-I digestion
enzyme ( 7ul + 2ul loading dye), sample 4 is double cut of DNA by Nco-I and Nhe-I digestion
enzymes ( 10ul + 2ul loading dye).
Sample 3 (single cut of DNA) preparations was done as following:
11.5ul dH2O+ 2ul 10X NE buffer+ 0.5ul Nco-I enzyme+ 6ul DNA.
Sample 4 (double cut of DNA) preparations was done as following:
10ul dH2O+ 2ul 10X NE buffer + 1ul BSA + 0.5ul Nco-I + 0.5ul Nhe-I + 6ul DNA.
Preparation of 1% Agarose gel was done as following:
o.6gm of Agarose powder + 60ml of 1X TAE buffer heated in the microwave then left to be
cooled, 3ul Ethidium bromide was added then poured in the gel casting tray.
After all samples were loaded the gel electrophoresis was ran at 90V for one hour then imaged
using UV Versa Doc imaging system.
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4.4.2.1.3. Transfection of Jurkat cells using polymer-based transfection reagent
Fugene-HD a polymer-based transfection reagent (Promega), was used to transfect Jurkat cells.
Fugene-HD is a mixture of lipids and other components in 80% Ethanol. It does not require any
ingredients of human or animal origin and also does not require removal of serum but using of
antibiotics (AB) in the transfection medium is not recommended. DNA concentration has to be
between 200µg/ml and 1mg/ml, its purity ( A260 / A280 ) has to be 1.7-1.9. The transfection
procedure was done as following:
Cells were plated in 96 well plate 20,000/100µl media+ serum but no AB. DNA ( at
concentration of 489 µg/ml and purity of 1.9) was diluted in 100µl free serum media then Fugene
transfection reagent was added to the diluted DNA at ratio of 6:1 (Fugene :DNA). (e.g. 2µg of
DNA and 6µl of Fugene). The mixture was incubated at room temperature (RT) for 10 minutes.
Cells transfection was done by adding 5 µl of this mixture to each well of the 96 well plate and
mixing gently by pipetting up and down 4 to 5 times. The plate was incubated at 37 0C for 24, 48,
72 and 96 hours, and cells were collected and cell lysate was prepared for total protein
calculations and Western blot to detect HSV1-tk expression.
4.4.2.1.4. Cell lysate preparation
Cells were counted and rinsed with cold PBS twice. (Washing and centrifuging). The final cell
pellet was prepared without any remaining phosphate buffer saline (PBS) (Thermo Scientific).
Lysis buffer was prepared by using RIPA lysate buffer (Thermo Scientific) 100 µl for each one
million cells containing 1µl Halt complete protease inhibitor and µl EDTA (Thermo Scientific).
Lysis buffer solution was added to the cell pellet, mixed by pipetting up and down many times
then incubated in ice at RT for 30 minutes. Then the mixture was spun at 3000 rpm for 10
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minutes at 40 C. The supernatant was aliquated and stored at -80 0C for the following
experiments.
4.4.2.1.5. Protein concentration determination in cell lysate
Protein assay kit (Pierce BCA ) ( Thermo Scientific) was used to determine the total protein
concentration in the cell lysate. Serial dilution of the bovine serum albumin (BSA) stock (2
µg/ml) in the RIPA lysis buffer (Thermo Scientific) was prepared as in table-1.
Table 4 Serial dilution of BSA in RIPA lysis buffer

A
B
C
D
E
F
G
H
I

BCA stock µl
200
90 from A
60 from A
60 from B
60 from C
60 from E
60 from F
56 from G
-

Diluent µl (RIPA
buffer)
Concentration(µg/ml)
2000
30
1500
60
1000
60
750
60
500
60
250
60
125
14
25
100
Blank

In eppendorf tubes all of the standard samples from A to I as on the table were prepared first.
Then in 96 well plate 10µl from A to I and 10 µl from our samples were put in duplicate. 200µl of
working reagent (mixing of BCA reagent A and reagent B at ratio 50:1) was added to each well.
The plate was put in the incubator, shaken for 30 sec then incubated without shaking for 30 min at
370 C. The samples were allowed to cool at RT for 5 min then were read at 595nm in the plate
reader and spectrophotometer to compare both measurements. The average OD of A to H was
used to make the standard curve and calculate total protein concentration in each sample.
4.4.2.1.6. Determination of the HSV1tk expression by Western blot
All samples were put at 1000 C for 5 min in the water path., for protein denaturation to expose
more epitopes (polypeptide fragment of the protein) to the primary antibody.
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A mixture of Laemmle’s sample buffer (Gen DEPOT) and plus one Mercaptoethanol (GE Health
Care - Biosciences) at ratio of 100:1 was prepared then added to samples at ratio of 4:1. Samples
were loaded in 10% poly acrylamide gel , then the gel was run for 90 minutes at 120V in the
running buffer (25mM Tris base ( Trizma) 4.53gm, 192 mM glycine 21.6gm, 7.5ml of % 20 SDS
solution and distilled water was add to total volume of 1.5 L) . Two molecular weight markers
were used: a) 2 µl of Xpert 2 Prestained protein marker (Gen Depot ) was used as rainbow marker
to confirm the transfer process, b) 2µl of Odyssey molecular weight marker (Li-Cor) was used for
quantification. The gel was transferred to PVDF membrane ( Immobilon transfer membranesMillipore) at 4 0C for 1 hour at 100 V in the transferring buffer (25mM Tris base ( Trizma)
4.53gm, 192 mM glycine 21.6gm, methanol 300ml and distilled water was added to total volume
of 1.5 L). Transfer buffer was Stored at 40 C for 30 to 60 minutes. Before the transfer process
the PVDF membrane was wet in methanol for 1-2 minutes then in cold transfer buffer for 5
minutes. The gel was equilibrated for 3-5 minutes in the cold transfer buffer before transferring.
The membrane was blocked using 10 ml of block buffer (Odyssey buffer Li-Cor ) in the shaker at
low speed at RT for 1 hour. Thymidine Kinase HSV-1 TK primary antibody (Santa Cruz
Biotechnology) and Beta Actin mouse mAB primary antibody (cell signaling) were diluted with
10 ml of Odyssey buffer and 20 µl of Tween 20 (Promega) at concentration of 1:10000. The
membrane was incubated with the diluted primary antibodies overnight on the shaker at low
speed at 4 0C. On the second day the membrane was washed four times with washing buffer (50
ml PBS + 50µl of Tween20) each time10 ml of the washing solution was added to the membrane
and put on the shaker at medium speed for 10 minutes. Secondary antibodies against HSV-1TK
(Donkey anti-Goat IRDye 680) (Li-Cor USA), and against beta-Actin (Donkey anti-Mouse
IRDye 800 CW (Li-Cor) were diluted at concentration of 1:10000. The membrane was incubated
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in the diluted secondary antibodies at RT on the shaker at low speed for 1 hour. The membrane
was washed exactly as previous step after primary antibody incubation. Then the membrane was
ready for imaging using Odyssey LX imaging system (Li-Cor).
4.4.2.2. Stable transduction of Jurkat, HEK 293, 4T1 and T cells using HSV1tk lentiviral
vector
To be able to image T cells for long periods of time, stable transduction using Vira Power
Lentiviral expression system (Invitrogen) was performed as follows:
An expression vector containing HSV-1 tk fusion gene pMOD-HSV1tk (Invitrogen) was
transformed to an E.coli bacteria strain GT100. The E coli bacteria was grown and the HSV1tk
plasmid extraction, concentration and purification was performed using same methods described
with the expression vector containing the HSV-1 tk fusion gene (pORF9-HSV-1tk: Sh ble).
To confirm the presence of HSV1tk gene, the pMOD-HSV1tk plasimed vector was cut ( single
and double cut ) using restriction enzymes (NcoI-HF and NheI-HF) then Gel electrophoresis
experiment was performed as described for the pORF9-HSV-1tk: Sh ble plasmid.
To ensure that the pMOD-HSV1tk Ecoli is expressing HSV1TK protein, the Ecoli was grown and
the optical density (OD) of 1.5 ml extraction of the E coli culture was measured using
spectrophotometer (Beckman Coulter DU 730) at wavelength of 600 nm. The reading was 2.2 (it
should be between 1.5 and 3.5). The bacterial cells were spun at 5000 rpm at 4 0C for 10 minutes.
Then cells were resuspended in 300 µl of the lysis buffer ( 25 mM TrisHCLpH=8, 0.1 M NaCl,
10% glycerol, 0.1 % Triton X-100 and 1mM PMSF) and vigorous overtaxing until the suspension
is homogenous. The bacterial lysate was spun at 13000 rpm at 4 0C for 5 minutes to separate
soluble proteins from insoluble proteins in the pellet. The supernatant was collected and stored at
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– 80 0C for Protein assay and western blot assay. Both of these assays were performed as
explained previously.
4.4.2.2.1. Purification of HSV1TK protein
Once the expression of HSV1tk was confirmed in the Western blot result, the HSV1TK protein
was purified from pMOD-HSV1tk Ecoli to be used as positive control for the following western
blots. The HSV 1-TK Protein purification was done as follows:
BL21/de3 E. coli were transformed with the pet21dTK plasmid and a stock of the transformant
was made and stored at –80 C. The bacteria were grown in LB medium at 37 C until the A600 =
0.5, then transferred to 18C, and when cooled 100 mg/l IPTG was added. The growth was
continued at 18 C for 18 hours, and then the bacteria harvested by centrifugation. Bacteria were
disrupted by a single pass through an Avestin emulsiflex operating at a pressure of 25000 psi, and
the lysate was clarified by centrifugation at 25000 rpm in and SW28 rotor for 30 min. The
histidine tagged TK was purified by chromatography on a nickel –NTA agarose column as
follows. The lysate was added to the column, and then the column was washed extensively with
25 mM tris, 300 mM NaCl, 10 mM imidazole until no 280 nm absorbing material eluted. The
bound protein was then eluted with 100 mM imidazole in the same buffer. Fractions containing
A280 absorbing material were checked by SDS gel electrophoresis. The protein containing
fractions were pooled, concentrated to 4 ml by ultrafiltration.
chromatographed on a sephacryl S200 column.

The material was then

The fractions were monitored by SDS gel

electrophoresis and TK containing peak fractions were pooled. Molecular weight =
about 41 KD, Residues = 374, Average Residue Weight = 109.242

40856.39

Charged = 1, Isoelectric

point = 8.00, Extinction coefficient = 38240 Therefore 1 mg/ml = A280 = 0.93
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4.4.2.2.2. HSV1tk Lentivirus construction
The pMOD-HSV1tk vector was cloned to pLenti6/UbC/V5/DEST (Lentiviral vector containing)
following the Vira Power system protocol.
containing

HSV1-tk

After the generation of the expression vector

(pLenti6-UBC-V5-DEST/pDONR221/HSV1tk).

This

vector

was

cotransfected to the 293FT cell line along with the packaging mix vectors ( pLP1, pLP2, and
pLP/ VSVG required to produce the lentivirus). The cotransfection was done using Lipofectamine
2000 transfection reagent based on cationic lipid-based formulation suitable for the transfection of
this cell line with high efficiency. The 293 FT cell line is a very suitable host for lentivirus
production. Then the viral supernatant was collected and titrated to be used for stable
transduction. Virus tittering was done following the Lenti-X GoStix kit (Invitroge). The final
virus concentration is 9.2 x 105 IU/µl. The production and tittering of HSV1tk lentivirus, was
made at the VCU Macromolecule Core Facility, supported, in part, with the funding from NIHNCI Cancer Center Core Grant 5P30CA016059-29
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Plasmid map of pMODHSV1tk

Lentiviral plasmid map in
which the HSV1tk was
cloned to.

attB2
HSV1tk
Kpn I (8185)
Kpn I (1012)

attB1
Kpn I (7582)

The final vector after
cloning which was used
for Lentivirus construction

Expression Clone/pLenti6-UBC-V5-DEST/pDONR221/HSV1tk
8795 bp

Figure 8 the pMOD-HSV1tk was cloned to pLenti6/UbC/V5/DEST and the result is pLenti6-UBC-V5DEST/pDONR221/HSV1tk (HSV1tk-Lentiviral vector).
67

4.4.2.2.3. Creating stable transduced cell line
HSV1tk-Lentiviral vector contains Blasticidin resistant gene instead of GFP as a selection marker.
Therefore a stable transduced cell line was created before T lymphocytes were transduced. Three
cell lines were used: Jurkat, HEK 293, and 4T1 breast carcinoma tumor cell line.
4.4.2.2.4. Transduction procedure
Cells were plated at concentration of 9.2 x105 in 2.5 ml of their complete media in 6 well plate in
duplicate. The virus stock was diluted in Opti-EMM reduced serum medium (Invitrogen) (10 µl
of the virus stock to 500µl of the media). The multiplicity of infection (MOI) defined as the ratio
of virus particles to the cell number was equal to 10. Polybrene (Millipore) at concentration of
8µg/ml was added just before the virus stock was added to cells. The diluted virus was added as
500 µl/ well gently drop by drop and cells were incubated at 37 0C for 24 hours. Then cells were
washed 3 times with their media was then incubated at 37 0C for 5 days to allow the HSV1tk gene
expression. The cells were split every other day and kept at concentration of 1 x106 /ml.
4.4.2.2.5. Selection of stable transduced cells using Blasticidin
As the pLenti6-UBC-V5-DEST/pDONR221/HSV1tk vector has a Blasticidin resistance gene, all
transduced cells should be resistant to Blasticidin. Based on this, Blasticidin (Invitrogen) was
used to select only stable transduced cells. To know the optimum concentration of Blasticidin that
will kill all cells, different concentrations of Blasticidin (1, 2, 4, 6 and 8µg/ml) were added to cells
(25 % confluent) in 6 well plate. Viability assay was performed every 3 days and fresh media
with Blasticidin at the same concentration was added. Cells were incubated with Blasticidin for
14 days. The optimum concentration for each cell line was determined. Then it was added on day
5 post transduction to all cell lines and cells were incubated for 14 days. This experiment was

68

repeated 2 to 3 times to make sure all transduced cells were selected. The transduced cells were
cultured for several weeks and some were frozen for following experiments
4.4.2.2.6. Confirmation of the presence of HSV1tk in the stable transduced cells by RT-PCR
To confirm the presence of the HSV1tk gene in the stably transduced cells, Real-Time
quantitative polymerase chain reaction (RT-PCR) was performed. Total RNA was extracted from
Jurkat, 4T1, and HEK cells (8 to 10 million of each) using Trizol reagent (Invitrogen). The
extraction procedure followed the reagent protocol. Then the RNA was purified using RNeasy
mini kit (Qiagen) following the kit protocol. The RNA concentration and purity was measured
using spectrophotometer. The purity in most of our experiments was 1.8. The RT-PCR
experiments were performed using the ViiA 7 system (Life Technologies) and TaqMan One Step
PCR Master Mix Reagents Kit (Applied Biosystems). All the samples were tested in triplicate
under the conditions recommended by the fabricant. The cycling conditions were: 48 0C/30min;
95 0C/10min; and 40 cycles of 95 0C/15sec and 60 0C/1min. HSV1 tk primers: forward:
CTCATGGCATGGGCAAGAC, reverse: CTCCTAGCACTCTCCAGTAGGTCAT,
probe: ACCACTCAACTGCTGGTGGCACTGG. Mouse beta actin was used as a housekeeping
gene for normalization. Beta actin primers: forward: ACG GCC AGG TCA TCA CTA TTG,
reverse: TCA CAC TTC ATG ATG GAA TTG AAT G. TaqMan probe: FAM- CCA GCC TTC
CTT CTT GGG TAT GGA ATC CT – TAMRA
Reactions were performed in the VCU Nucleic Acid Research Facilities.
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4.4.2.2.7. Detection of the HSV1tk expression in the stably transduced cell lines by Western
blot
Transduced and untransduced cells (Jurkat, HEK and 4T1 ( 10 x 106 of each)) were lysed after 2
rounds of selection period using Blasticidin post-transduction and the total protein concentration
was calculated using a protein assay kit; then western blot was done using 300 µg of the total
protein as explained previously.
4.4.2.2.8. Radiosynthesis of [124I]-FIAU (synthesis, mechanism of trapping by cells and
characterizations)
[124I]-FIAU was synthesized as described previously [64] with some modifications as shown in
Scheme 2. Briefly,

124

I was produced on the IBA Molecular cyclotron using the

nuclear reaction on an enriched

124

124

Te(p,n)124I

TeO2/Al2O3 solid target. The 2’-fluoro-2’-deoxy-1-β-D-

arabinofuranosyl-5-(tri-n-butyltin)-uracil (FTBSnAU) precursor (0.5 to 1 mg) was dissolved in 50
µL methanol and added 1 to 15 mCi (100 µL 0.1 M NaOH), followed by the addition of a 100-µL
mixture of 30% hydrogen peroxide/ acetic acid (1:3, v/v). Reaction mixture was sonicated for 20
min at room temperature. After confirmation by radio- Thin Layer Chromatography (radio-TLC)
(BIOSCINCE AR-2000) and radio-High Performance Liquid Chromatography (radio-HPLC)
(Waters 1525), aqueous saturated sodium metabisulfate (100 mL) was added to quench the
reaction. Then the reaction mixture was loaded onto a preconditioned (10mL water-ethanolwater) tC18-1gm Sep-Pak cartridge system (Waters, Milford, MA). The tC18 cartridge system was
eluted with water (5 mL), followed by methanol (3–4 mL) to isolate the 124I-FIAU. The methanol
was evaporated and the

124

I-FIAU was formulated in PBS for in-vitro and in-vivo study. Final

product was analyzed by Rado-TLC and Radio-HPLC by co-elution with FLT standard. The
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radiolabeled product was isolated in 95% radiochemical yield, with radiochemical purities of
97%.

Scheme 2: Radiosynthesis of [124I] FIAU

HSV-1TK enzyme

[ 124I ] FIAU free

[124I ] FIAU trapped in the cell

Scheme 3 Mechanism of [ 124I] FIAU trapping by cell. Viral Thymidine kinase enzyme (HSV1TK) transfers a γ phosphate group from ATP to the 5’ hydroxyl group of pyrimidine
deoxynucleosides. The lipophilic tracer diffuses into the cell and is phosphorylated by HSV1-TK
enzyme activity, and trapped within the cell.

Radio-TLC was performed using radio–thin-layer chromatography (silica gel plates [SigmaAldrich, St. Louis, MO]; eluent, ethyl acetate/acetone/H2O, 14:8:1) as shown in Figure 9.
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A

B

Figure 9, Radio-TLC of [124I]-FIAU before purification (panel A) and Radio-TLC of [124I]-FIAU
after purification (panel B).

Radio-HPLC analysis: The [124I]-FIAU was analyzed by radio-HPLC using the following
conditions: using column C-18 luna Phenomenex 5µ C18 150 x 4.6 mm, mobile phase 10%
Ethanol in 0.05 Molar NaH2PO4 at flow rate 1 mL/min, UV 2254 nm. The radiochemical identity
was confirmed by co-injections with non-radioactive standard FIAU compound (Figure 10), and
gave the same retention time as [124I]-FIAU, = 8.6 min.
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A

B

Figure 10, HPLC profile of [124F]-FIAU (panel A) spiked with standard cold FIAU (panel B).

A

B

Figure 11, HPLC profile of [124F]-FIAU (A) before Sep-Pak purification, and after Sep-Pak
purification (B).
4.4.2.2.9. 124I- [FIAU] uptake by Jurkat, 4T1 and HEK cells
Transduced and untransduced Jurkat cells were put in gamma counting tubes at a concentration of
5x106 / 3 ml of media in triplicate. Transduced and untransduced HEK 293 and 4T1 cells were
plated in 12 well plate at of 300 x105 cells / 2 ml of media in triplicate. 124I- [FIAU] was added at
concentration of 1µci/ml. Cells were incubated at 37 0C for different time points (1, 2, 4 and 18
hours). After each time point cells were spun at 1500 rpm at 4 0C for 8 minutes and cell
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supernatant was collected for counting. Cells were washed 3 times with PBS and all wash was
collected for counting. 50µl of cold PBS was added to the cell pellets and 50 µl of the supernatant
and the wash was taken for counting. The % of cell uptake was calculated as following:
% uptake = (CPM of cell pellets)/ (CPM of sum of cell pellet, cell supernatant, cell wash)
multiplied by 100
4.4.2.2.10 T lymphocytes transduction
T lymphocytes were isolated, activated and expanded as described previously. After the 18 hours
incubation with Bryostatin/Ionomycin (B/I) cells were washed three times with warm, complete
RPMI and resuspended at 1–2 x 106 cells/ml with 40 U/ml of IL-2 or with IL-7 and IL-15 (10
ng/ml each) for 48 hours . On day 3 post expansion, cells were transduced with HSV1tk
Lentivirus at different MOIs (10, 5, 2, 1, 0.2 and 0.03) to determine the best MOI for our in vivo
studies. Cells were then plated at 1x106 cells /ml in 24 well plates. Polyberene (as transfection
reagent used to increase the transduction efficiency) was added at 8µg/ml just before cells were
plated. Cells were incubated 37 0C for 4 hours. Then cells were washed with media 3 times and
incubated at 37 0C for 6-7 days. Cells were resuspended and fresh media with fresh cytokines was
added every other day and cells kept grown at concentration 1-2 x106/ml.
4.4.2.2.11. Detection of HSV1tk expression in transduced T lymphocytes
To check if the T lymphocytes were successfully transduced or not, real time PCR and western
blot were performed as follow:
In order to determine the changes in the expression level of HSV1tk with time, on days 1,3,5,and
7 post transduction, transduced and untransduced IL-2 and IL-7/15 at were collected and counted
and about 20 x 106 of each were used for real time -PCR. The procedure was done as described
previously.
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The HSV1TK protein was detected using Western blot assay. Transduced and untransduced IL2
and IL7/15 T cells (25 x 106) were lysed and the total protein concentration was calculated using
protein assay kit; then western blot was done using 300 µg of the total protein as explained
previously.
4.4.2.2.12. Transduced T lymphocytes proliferation and viability
Cell proliferation was assessed based on cell number and fold increase calculation every other
day. Fold increase was calculated as the ratio of cell number each other day compared to the cell
number immediately after pulsing with B/I.
The cell viability at different MOIs was assessed using Cell Titer Glo Luminescent assay kit at
different time points post transduction. Transduced and untransduced cells were plated in
triplicate 96 well plates at 25000cells/100µl of media. The kit reagents were mixed and added to
cells according to the kit protocol then was read by the plate reader ( DTX 880 Multimode
detector Beckman Coulter) at 580 nm. The % viability was calculated for each group in
comparison to unlabeled cells and expressed as % of viability.
4.4.2.2.13. Transduced T lymphocytes phenotyping
To investigate whether there is any effect of the transduction on the T lymphocyte phenotype; T
lymphocytes were stained and tested using flow cytometry. Four groups of T cells (IL2
untransduced and transduced cells, and IL7/15 transduced and untransduced cells) were double
stained with CD8 or CD4 /CD62L or CD8 or CD4/CD69 antibiotics. One million of cells for each
group was used in duplicate and stained with PECY5 anti mouse CD4 antibody, FITC anti mouse
CD8 antibody, PE anti mouse CD69 antibody and PE anti mouse CD62L antibody (Bio Legend).
The antibody concentration was 1µg/million of cells and FC (CD16/ CD32) block was used at the
same concentration to remove any non-specific staining. Cells were resuspended in 2% FBS in

75

1X PBS and incubated with the antibodies for 30 minutes in a dark room, then spun and washed
twice in 1X PBS with 2% FBS. Cells were tested using flow Cytometry to compare the
percentages of CD8/CD69 and CD8/CD62L between transduced and untransduced cells.
4.4.2.2.14 Interferon- γ production pre and post transduction
To examine the interferon-γ production from T lymphocytes before and after transduction, the
ELISA assay was performed. 4T1 tumor cells were irradiated using Gamma cell 40 Exactor
system (10,000 rad for 30 to 60 minutes) to stop their proliferation. The irradiated cells were
counted and brought to 1 x 106 /ml. On day 6 post transduction, the transduced and untransduced
T lymphocytes (grown in IL2 or IL7/15) were plated in 24 well plates at 2 x 106 / 2 ml
concentration. The irradiated 4T1 cells (200µl) were added to each well (1:10 dilution) and
incubated overnight at 37 0C. The interferon-γ (INF-γ) protein released into supernatants was
collected and assayed using BD OptEIA mouse INF- γ ELISA kit (BD Biosciences, San Jose,
CA). All samples were tested in duplicate and 8 groups were analyzed: 1) transduced IL2 T
lymphocytes + 4T1 cells, 2) untransduced IL2 T lymphocytes + 4T1 cells, 3) Nil transduced IL2
T lymphocytes, 4) Nil untransduced T lymphocytes, and similar 4 groups for IL7/15 T
lymphocytes. (Nil stands for T cells incubated alone without irradiated 4T1 cells).
4.4.2.2.15. 124I- [FIAU] uptake by T lymphocytes
Transduced T cells (IL-2 and IL-7/15cells) and transduced Jurkat cells were put in gamma
counting tubes at concentration of 5x106 /3ml of their media in triplicate.

124

I- [FIAU] was added

at concentration of 1µCi/ml. Cells were incubated at 37 0C for different time points (1, 4 and 18
hours). After each time point, cells were spun at 1500 rpm at 4 0C for 8 minutes and cells
supernatant was collected for counting. Cells were washed 3 times with PBS and all wash was
collected for counting. 50µl of cold Lysate buffer (RIPA lysate buffer) was added to the cells
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pellets and 50 µl of the supernatant and the wash was taken for counting. The % of cell uptake
was calculated as following:
% of uptake = CPM of cell pellet/ CPM of sum of cell pellet, cell supernatant, cell wash
multiplied by 100.
4.4.2.2.16. Multi-labeled T lymphocytes trafficking and imaging (Optical & PET)
Transduced and untransduced IL2 and IL7/15 T cells were labeled with DiR at 320µg/ml
concentration as described previously. For development of tumor models, animals were
inoculated subcutaneously into the right flank with 4T1 breast carcinoma tumor (5 x 104) and
allowed the tumor to grow for 10 days. One day before injection of labeled T cells, animals were
pretreated (ip) with 100mg/kg Cyclophosphamide to reduce the number of T regulatory cells by
increasing the number of effective CD8 and CD4 cells. The transduced and untransduced T cells
were prepared (10 x106 in 0.5 ml PBS per animal) and injected i.v. via tail vein into four groups
of animals (IL2 transduced-6 animals, IL2 untransduced-3 animals, IL7/15 transduced-6 animals
and IL7/15 untransduced-3 animals) were injected (tail vein injections) with

124

I [FIAU] (activity

between 300 to 500 µCi). Because the imaging time was carried out for two weeks and the halflife of

124

I is 3.8 days, the activity of

124

I [FIAU] was injected in the first and second week of

imaging. The multi-spectral fluorescence imaging was established as described previously.
4.4.2.2.17. Biodistribution study
In order to track and localize the transduced T cells post

124

I [FIAU] injections into the four

groups of animals, biodistribution study was carried out at different time points (day 3 and day 10
post radionuclide injections). Animals were dissected on day 3 post first radionuclide injections
(3 animals from each transduced cells group) and the other 3 animals with the untransduced cells
groups were dissected on day 10 of imaging and it was day 3 post the second injection. Most of
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the animal tissues were collected and their activities in CPM were measured using Gamma
counting system (1282 COMPUGAMMA CS universal Gamma counter). The % ID/g of each
tissue was calculated using the following formula:
% ID = 100 x tissue activity (µCi) / injected activity (µCi) x tissue mass (g)
Tissue activity in µCi was calculated from tissue activity in CPM converted to dpm using
efficiency factor as following:
dpm = CPM / efficiency factor , 1 µCi = 2.22 x 106 dpm.
Efficiency factor was calculated by measuring 4 different activities of [ 124I ] FIAU
( 2.1399±0.7912, 2.7959±0.6867, 4.1044±0.5687 and 3.1908±0.6438) in µCi using Gamma
Spectrophotometer system ( ORTEC-50 AMETEK) and same activities were measured in CPM
by gamma counter. Then DPM was calculated by multiplying activities measured in µCi by
2220000. The efficiency factor is CPM/DPM, which is 0.31 for 124I in our measurements and was
used for our Biodistribution study calculations.
4.4.2.2.18. Detection of HSV1TK at some organs in vivo
Some of the organs (liver, lungs, spleen, tumor and lymph nodes) were collected after animal
dissection and immediately were snap frozen in liquid nitrogen. Protein assay and Western blots
were performed as described previously to verify the localization of transduced T cell at these
organs.
4.5. Studying the trafficking pattern of T lymphocytes to 4T1 metastasis
The final objective in this project was, to study the trafficking pattern of IL2 and IL7/15 T cells to
4T1 tumor metastasis. 4T1 cells were successfully transduced with HSV1tk gene as verified by
RT-PCR and western blot. Transduced 4T1 cells were implanted in the abdominal fat mammary
pad of some of animals (orthotopic tumor) and others were implanted in the right flank of the
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animal and untransduced 4T1 tumor was implanted in the left flank. PET imaging was performed
on the third and fourth week post tumor implantation. Firefly-luciferase expressing T cells were
provided kindly from Dr Bear’s lab and injected i.v. on the third week post 4T1 implantation into
the abdominal fat mammary pad animals and bioluminescence imaging were performed for one
week. Then animals were dissected and Western blot of some organs was performed.

4.6. Statistical analysis
The significant differences in the ex vivo and in vivo studies were determined using the equal
variance analysis (ANOVA) (JMP software), or Student’s t-test. P value of < 0.05 was considered
as statistically significant difference. The data shown in graphs are mean ± SEM.
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Chapter Five: Results
5.1. Direct labeling of T lymphocytes using DiR probe
5.1.1. DiR signal detection and labeling efficiency
To test how long the DiR signal is maintained after staining of cells, DiR labeled T lymphocytes
were cultured and imaged at different time points. DiR labeled cells (0.5 or 1.0 x 106 per well )
were washed and plated in 6 well plates at each and time point then imaged up to 9 days. The
result showed good signal maintenance and detection for more than one week (Figure 12, panel
A). The efficiency of DiR labeling of T cells was tested using flow Cytometry (Figure 12 panel
B). The result showed that nearly 100% of cells were labeled.

1.0x106

0.5x106

A

80

B
94.0%

T cells stained
for CD3

DiR labeled
T cells

MFI: 3,899

DiR + CD3
T cells

MFI: 4,524

Figure 12 DiR labeled T cells were imaged at different time points up to day 9 (Panel A). DiR
labeled T cells showed detectable signal for more than one week. On days 7 and 9 only few cells
were left, that’s why only half million of cells were plated. Even on day 9 the DiR signal looks
stronger than previous days, because of the fluorescence quenching phenomenon. This means
decrease of the fluorescence signal given from too much intense fluorescence material. In our
case, as cells divided the DiR is diluted with each division and the DiR become more and more
diluted (less intense) leading to prevent fluorescence quenching and increase DiR fluorescent
signal. Panel B is flow cytometry data showed that the mean fluorescent intensity (MFI) is
increasing with DiR labeled CD3 T cells and the labeling efficiency with DiR is 94 %.

5.1.2. DiR labels T cells with negligible transfer to tumor cells
DiR has two long 18- carbon chains that insert into the cell membrane, which showed specific and
stable cell labeling with negligible transfer between cells. To test this property of DiR, T
lymphocytes were labeled with DiR and incubated with 4T1 tumor cells for 24 hours in 6 well
plates. Then DiR labeled T cells were washed out from 4T1 cells wells (T cells are flouting cells
and 4T1 are adherent cells). Multi-spectral fluorescent imaging system was used to image the
plates (Figure 13). The DiR signal was clearly detected in the DiR T cell well, but not in the DiR
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T cells + 4T1 tumor cells well, indicating that, DiR specifically labeled T cells and did not
transfer to 4T1 tumor cells.
Fluorescent imaging

DiR T cells

DiR T cells +4T1 cells

Post spectral un-mixing

DiR T cells

DiR T cells +4T1 cells

Figure 13 DiR labeled T cells incubated with 4T1 tumor cells for 24 hrs, showed
negligible to no transfer between both cells. (Post Spectral un-mixing refers to auto
fluorescence signal subtraction and show only DiR signal)
5.1.3. Cell proliferation pre and post labeling were comparable
The proliferation of 4T1 sensitized T lymphocytes isolated from tumor DLN activated with B/I
and expanded in IL-2 or IL-7 + IL-15 containing media was observed for 10 days. Since the
number of T lymphocytes from day 6 was high (figure 14), these cells were labeled with DiR to
be adoptively transferred into 4T1 tumor bearing mice, and the effect of labeling cells with DiR
on proliferation was determined. The results confirmed that, cells labeled with DiR showed
similar proliferation as the unlabeled T cells (Figure 14). Both unlabeled and labeled cells
continue to proliferate at the same rate until day 4 post-labeling (day 10 of expansion). These
results showed that labeling of cells with DiR does not affect the proliferation of the T
lymphocytes grown in the presence of IL-2 or IL-7 + IL-15 even for 10 days of expansion.
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Figure 14 T cell proliferation based on viable cell counts on each day compared to the number of
cells on day 1 of ex vivo expansion. Cell number was highest on day 6. Therefore, this was the
chosen time for labeling. Furthermore, no significant differences between labeled and unlabeled
cell proliferation post-labeling. (Fold increase in cell number is the number of cells at each day
pre or post labeling compared to the cell number on day 1 directly after the activation in B/I)

5.1.4. DiR labeled cells showed 80-90 % viability when labeled using 320µg/ml of labeling
solution
The viability of lymphocytes labeled with various concentrations of DiR was assessed to
determine the optimum non-toxic concentration with which cells could be labeled. Since T cells
which have been B/I activated and expanded in IL-2 or IL-7+IL-15 containing media for six days
were used for in vivo studies, the viability of cells from day 6 onwards was monitored, when
labeled with DiR and compared with unlabeled T cells. The results show that there were no
significant differences in % viability among the various concentrations of DiR tested compared to
unlabeled cells on days 1 and 4 post-labeling. However there is a significant difference (p < 0.05)
in the viability of cells recovered on day 7 compared to viability tested at unlabeled cells and to
days 1 and 4. Since on days 1 and 4 the cells were 80-90% viable even at the highest
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concentration of DiR used (320 µg/ml), this concentration was used for further in vitro and in vivo
studies (Figure 15 Panel A, Panel B)) as the higher amount of DiR on cell membranes is likely to
allow signal retention and in vivo detection for relatively longer durations.
Tumor sensitized lymphocytes were labeled with 320µg/ml of DiR and on day 2 and 7 postlabeling, were incubated with Annexin V/PI to determine the cause of cell death. The flow
cytometry results showed that, the cell viability of unlabeled and labeled cells was comparable
(figure 16). As explained previously, cells grown in IL7/15 higher viability than cells grown in
IL2 regarding of labeling.
A

Day1

IL2 cells
IL2 cells

120

Day4
Day7

% of Viability

100
80

*,#

*,#

*,#

*,#

*,#

60
40
20
0
0

3.5

14

56

224

320

DiR Concentration (ug/ml)

B

IL7/15 cells

120

Day1
Day4

% of Viability

100

*,#

80

*,#

*,#

*,#

*,#

Day7

60
40
20
0
0

3.5

14

56

224

320

DiR Concentrations ug/ml

Figure 15 Percent viability of T cells labeled with various concentrations of DiR measured using
Cell TiterGlo assay. Bryostatin/Ionomycin (B/I) activated 4T1-cells grown in IL-2 were labeled
on day 6 of their ex vivo expansion. Viability of T-cells 1, 4 and 7 days post-labeling was
compared with unlabeled cells and expressed as percent viability. * and # means there is a
significant difference in the cell viability between day 1 to day 7 and day 4 to day 7 respectively.
These differences were more observable with IL2 cells than IL7/15 cells. Cells showed 80 to
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90 % viability on days 1 and 4 post-labeling and no significant differences compared to unlabeled
cells. On day 7 post-labeling which is day-13 post-labeling, cell viability was 60% or below and
showed significant differences compared to unlabeled cells because these are primary cells and
their viability decreases beyond day 10 of ex vivo expansion. Average ±S.D from three different
experiments are shown in the graph.
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Figure 16 T cells % of viability tested by flow cytometry (apoptosis kit). DiR labeled cells were
tested on days 2 and 7 post labeling. All results showed that, the viability of DiR labeled cells is
somehow higher than unlabeled cells, indicating that, DiR probe does not affect cell viability.
5.1.5. Interferon-γ production in vitro and in vivo
In vitro activated 4T1 sensitized T cells were expanded for 6 days, and incubated (either
unlabeled or DiR-labeled) with irradiated 4T1 tumor cells or MethA tumor cells for 24 hours in
IL-2 or IL7/15 containing media. The levels of IFN-γ in the supernatant were determined. The
results showed that, with time there is accumulation of IFN-γ in the media but there is no
significant difference in the IFN-γ levels in the supernatant of T cells, incubated alone compared
to T cells incubated with non-specific Meth A tumor (Figure 17 panels A & B) on respective
days. However, T cells incubated with 4T1 tumor cells showed significantly higher release of
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IFN-γ into the media (p<0.05) than cells incubated alone (Nil cells) or with Meth A tumor. Since
no significant differences in cytokine levels released were observed between unlabeled and
labeled T cells, the data also demonstrate that labeling the cells with DiR does not affect their
interaction with tumor cells. Figure 17 panel C shows that, the amount of IFN-γ in the mice
bearing 4T1 tumor which have been injected with labeled T cells, is higher in their blood serum
compared with mice bearing 4T1 tumor only (no T cells infused) and mice bearing Meth A and
which have been injected with labeled T cells.
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Figure 17 The amount of interferon-γ released in the cells supernatant and in vivo mice serum
showed higher amount of this cytokine in both cases, when the 4T1 specific T cells or in the mice
injected with 4T1 specific T-cells compared to other groups as shown in panel A, B and C.
5.1.6. Multi-spectral fluorescent imaging of T cell trafficking
Adoptive transfer of DiR labeled 4T1 sensitized T lymphocytes which had been expanded
in vitro for 6 days, were administrated intravenously 4 day or one week after tumor implantation.
Imaging of the mice using Maestro-2, revealed homing of 4T1 sensitized lymphocytes to the site
of 4T1 tumor. The signals from DiR labeled cells persisted in tumor bearing mice for up to 21
days (Figure 18A). The tumor/Background ratio (Tumor/BKG Ratio ) shows that the peak signal
intensity is obtained on day 6 after adoptive transfer, following which the signal intensity started
to gradually diminish (Figure 18C). In contrast, when the 4T1 sensitized lymphocytes were
injected into a Meth A tumor bearing mice, there was no migration of DiR labeled cells to the
tumor site. This is indicated by lack of fluorescence signal obtained from the tumor site (Figure
18, panel B). This suggests that these IL-2 grown T cells are antigen specific. For T cells grown in
IL7/15, their signal was lower than IL2 cells signal and peaked on day 8 (figure 20). This may
due to the IL7/15 in vivo proliferation at the tumor site. They proliferate more than IL2 cells,
which may lead to the dilution of the labeling probe and reduced signal.
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Figure 18. Fluorescence imaging of T cell trafficking. Homing of 4T1 sensitized DiR labeled T
cells to (Panel A) 4T1 tumor site (green color codes for Autofluorescence signal , and red color
codes for DiR signal ), (Panel B) Meth-A carcinoma tumor site (used as negative control tumor) 4
days after the tumors have been implanted. Red color indicates the signal from the NIR DiR Dye
used to label the T cells. (C) Tumor/ Background ratios graph showed that, cells localized at the
tumor site on day 1 peaked on day 6 and persisted up to 21 days in the animal. While in case of
Meth A tumor, there was no localization of 4T1 specific T cells at the tumor site.

To determine whether signals from DiR labeled 4T1 sensitized T cells can persist in vivo for a
prolonged period of time, 4T1 tumor cells were introduced one week after the mice had already
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received infusion of activated/expanded T cells. Interestingly, the T cells migrated to the site of
tumor as early as 2 hours post injection of tumor cells and the signals from DiR tagged T cells
were detectable for more than 2 weeks (Figure 19A). Further examination of the
tumor/background (BKG) ratio revealed that the signal intensity had increased modestly on day 3
and then began to gradually decline (Figure 19 B).
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Figure 19. Fluorescence imaging of T cell trafficking (A) Adoptive of 4T1 sensitized T cells
expanded in IL-2 media, injected one week prior to 4T1 challenge. The labeled 4T1 specific T
cells were able to leave the lymphoid compartment and localized at the tumor site in 2 hours.
Green color denotes Autofluorescence and the Red color denotes the signal from DiR labeled
lymphocytes. (B) Tumor/ Background ratios obtained from mice injected with T cells and
90

inoculated with 4T1 cells a week later. The graph showed the signal appeared on day 1 (on the 2
hours image) peaked on day 3 and persisted 21 days in the mice.
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Figure 20 Tumor/ Background ratios graph of animals bearing 3 days 4T1 tumor and injected
with IL7/15 cells. The graph showed that, cells localized at the tumor site on day 1, peaked on day
8 then decreased sharply with time up to 21 days in the animal.
To confirm that the signal that was detected at the tumor site was linked to viable DiR labeled T
cells, a cell lysate was injected in number of animals and imaged at different time points starting
from day 1 to day 14. No signal was detected at the tumor site or lymph nodes in the cell lysate
group. However, there was signal detected in lung, spleen and liver because of the route of
administration (i.v. injections of cell lysate). In contrast, after infusion of viable DiR labeled cells,
tumor and lymph nodes showed detectable signal which increased with time, indicating that more
T cells are migrated or proliferated at these sites.
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Figure 21 Fluorescence imaging of IL2 cell trafficking. Homing of 4T1 sensitized DiR labeled
cells to 4T1 tumor site 7 days after the tumors have been implanted (panel A), Panel B fluorescent
imaging of animals injected with the IL2 cell lysate supernatant. Red color indicates the signal
from the NIR DiR Dye used to label the T cells. (C) Tumor/ Background ratios graph showed
that, cells localized at the tumor site on day 1(on 2hrs) peaked on day 3 and persisted up to 14
days in the animal. While in case of IL2 lysate, there was no localization of 4T1 specific T cells at
the tumor site.
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Figure 22 Fluorescence imaging of IL7/15 cell trafficking. Homing of 4T1 sensitized DiR labeled
cells to 4T1 tumor site 7 days after the tumors have been implanted (panel A), Panel B fluorescent
imaging of animals injected with the IL7/15 cell lysate. Red color indicates the signal from the
NIR DiR Dye used to label the T cells. (C) Tumor/ Background ratios graph showed that, cells
localized at the tumor site on day peaked on day 3 and persisted up to 14 days in the animal.
While in case of IL7/15 lysate , there was no localization of 4T1 specific T cells at the tumor site.

5.1.7. Localization of labeled T-lymphocytes at tumor and non-tumor tissues
To investigate the migration pattern of 4T1 sensitized T cells following inoculation to sites
besides the tumor site, tumor bearing mice were dissected at various time points following
inoculation with DiR labeled T cells and different organs were removed and imaged ex vivo.
Besides tumor, labeled T lymphocytes were also seen to have localized to liver, spleen, lungs,
lymph nodes and bone marrow, as shown in Figure 23 panels A, B,C and D. Figure 23 panels E
and F show signal to background ratio of labeled T-lymphocytes in these organs on days 3 and
10 post-injection of labeled T cells. The signal increased modestly with time, which would
indicate that additional labeled cells were migrating to these sites.
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Figure 23 panels A,B,C and D Fluorescence imaging of tumor, liver, lungs, spleen, and
bone marrow ex vivo. (E,F) Quantitation of the signal from labeled T-lymphocytes at the
tumor site and other organs on days 3 and 10 post T-cells administration.
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5.1.8. T cells specificity and their AIT function with or without DiR labeling in vivo
To test the specificity of T cells as antigen specific cells for 4T1 tumor with and without
labeling with DiR and their immune function in vivo, number of animals were classified into 8
groups ( 6 animals in each), group 1 animals with 4T1only ( control 4T1) group 2 same as group
1 for Meth A tumor (control meth A), group 3 animals with 4T1 injected with
cychlophosphamide (CYP) only (CYP 4T1), group 4 same as 3 but for Meth A (CYP Meth A),
group 5 animals injected with T cells and CYP ( CYP 4T1 AIT), group 6 same as group 5 but for
Meth A (CYP Meth A AIT), group 7 and 8 same as groups 5 and 6 but T cells were labeled with
DiR (CYP AIT 4T1 DiR) and ( CYP AIT Meth A DiR).

The tumors were implanted

intradermally in the left flank, CYP was given on Day 3, and AIT (ex vivo activated T cells with
and without labeling with DiR) on Day 4 after tumor implantation. Tumor volume was measured
for about one month post treatment. Figure 24 showed the results of this experiment; two
important observations are noticed; first T cells are antigen specific against 4T1 tumor and no
activity was observed against Math A tumor. This result is consistent with our previous data
shown in figure 18. Second, DiR does not show any effect on the T cells function in vivo after
adoptive transfer.
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Figure 24 T cells with and without DiR labeling function in vivo against 4T1 and Meth A tumors.
Panel A T cells activity against 4T1 tumor, tumor volume was zero starting from day 6 after AIT
(T cells with or without DiR labeling) administrations. Control and CYP groups showed an
increase in the tumor volume as time increases. Panel B T cells activity against Meth A tumor, no
decrease or regression in the tumor volume with time and no differences compared to other
groups (control and CYP), indicating that T cells are antigen specific against 4T1 tumor.
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5.1.9. Immunohistochemistry confirms localization of activated T cells at the tumor site
To confirm the localization of the activated T-lymphocytes to the tumor site, 5 micron thick
tumor sections from mice inoculated with DiR labeled T cells were stained for CD69 and F4/80 to
detect activated T-lymphocytes and macrophages respectively. Both activated T lymphocytes and
macrophages were visualized at the tumor site as shown in Figure 25. A, B, C and D are different
sections of the tumor from outside to deep inside the tumor. The activated T lymphocytes were
mostly localized at the superficial layer of the tumor; macrophages were localized deeper inside
the tumor tissues. To ensure that the localization of macrophages at the tumor site was not to
attack and engulf labeled activated T-lymphocytes, we implanted 4T1 breast carcinoma tumor in a
number of mice and dissected them after 10 days when they have the same tumor size as in our
previous experiments. These mice were not injected with activated T lymphocytes. Tumors were
sectioned, double stained for CD69 and F4/80 and then imaged. Figure-25 E, F, G and H illustrate
the images of these sections, and we did not see any activated T cells at these tumors and this was
expected. Spleen sections were used as positive control for T-lymphocytes. Whereas, liver was
used as positive control for macrophages, both spleen and liver images are demonstrated in
Figure-25 E and F.
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Figure 25 (A-B) Mouse bearing 4T1 tumor was injected with activated T-cells and the tumor
sections were stained for CD69 activated T-cells (red color) marker and F4/80 macrophage (green
color) marker. (C-D) Images of 4T1 tumor sections obtained from mouse bearing 4T1 tumor but
not injected with activated T cells, stained for CD69 and F4/80 markers. (E) Spleen section
stained for CD69 (used as positive control for activated T-cells) and (F) Liver section stained
F4/80 (used as positive control of macrophages).

5.1.10. Confirmation of immunehistochemistry results by flow cytometry
To validate that adoptively transferred labeled T cells (AIT) are not engulfed by
macrophages or the DiR is transferring to other immune cells, tissues (liver, spleen, bone marrow
(BM) and tumor) that showed high accumulation of T cells were collected and digested on day 7

99

post AIT injections. Following tissues were also stained for macrophages (F4/80) and immune
cell marker (CD45) for flow cytometry analysis. CD45 is expressed on almost all hematopoietic
cells except for mature erythrocytes. We are testing if DiR is associated with any other cells than
T cells, particularly macrophages and other hematopoietic cells. The result (figure 26) shows that
no DiR was associated with F4/80 or CD45 indicating that, DiR is linked to T cells and did not
transfer to other cells.
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Figure 26 assessment of immunohistochemistry result by flow cytometry. Panel A tissues were
stained for macrophages (F4/80), panel B tissues were stained for immune cell marker CD45.
Both confirm that DiR is linked to T cells and no transfer of DiR to other cells.

5.1.11. Verification of DiR labeled cells localization at tumor site
To validate whether the DiR signal at the tumor site is connected to the DiR labeled cells, DiR
stock was diluted and prepared in PBS as described previously and injected to number of animals
bearing 4T1 tumor. Fluorescent imaging was done at 3 time points (2, 24 and 48 hours post i.v.
injection). The animals were dissected after 48 hours and organs were removed and sectioned.
Figure 27 showed the fluorescent images of liver, heart and tumor sections. No signal was
detected at the tumor section indicating that, the DiR signal at the tumor site connected to DiR
labeled T cells.

Liver

Heart

4T1 tumor

Figure 27 fluorescent images of liver, heart and 4T1 tumor sections of animal injected with DiR
only. From the ex vivo imaging higher signal was detected in the liver and no signal was in the
heart, that is why liver was used as positive and heart negative controls. 4T1 tumor section
showed no signal of DiR indicating that, the signal detected at the tumor site is correlated to DiR
labeled cells.

5.2. Indirect labeling of T lymphocytes by PRG (HSV1tk)
5.2.1. Transient transfection by transfection reagent
To optimize the HSV1tk gene expression detection, transient transfection was performed with
Jurkat cells. pROF9-HSV1 tk-sh plasmid was isolated from GT116 Ecoli and was then cut to
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single and double cuts using restriction enzymes to perform gel electrophoresis assay. The result
shown (figure 28) confirmed the presence of HSV1tk gene in the Ecoli plasmid. According to the
band size calculations in relation to the DNA ladder, bands 3 and 4 showed HSV1tk size exactly
as shown in the plasmid map.
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Figure 28 Gel electrophoresis result (panel A) confirmed the presence of HSV1tk gene.1 and 5
DNA ladder, 2= plasmid intact DNA move as coils can’t calculate its size, 3= single cut Using
NcoI restriction enzyme (linearized plasmid) (first band= 4580bp), 4= double cut using 2
restriction enzymes NcoI, and NheI (first band = 4580bp- (2148bp-561bp) = 2993bp)(Second
band = 2148bp-561bp = 1587bp). Panel B showed pROF9-HSV1tk-sh plasmid map.

The HSV1tk vector was used for transient transfection of Jurkat cells. Figure 29 shows the
western blot result post transfection using polymer based transfection reagent (Fugene). Ecoli

A

lysate was used as positive control for HSV1TK protein. Cells showed expression of the gene up
to 4 days (the end of cell lysate collection). This experiment was done to optimize western blot
protocol and make sure the primary antibody is specific for HSV1 TK enzyme.
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Tranfected jurkat cells
expressing HSV1TK

Figure 29 western blot result of transfected jurkat cell exhibit HSV1 tk expression in jurkat cells
at different time points post transfection.
5.2.2. Stable transduction by HSV1tk lentivirus
5.2.2.1. Confirmation of the presence of HSV1tk gene in pMOD-HSV1tk plasmid
HSV1tk gene was transformed to pMOD-HSV1tk plasmid (GT100 Ecoli,) and then was extracted
to be cloned to the lentiviral vector to construct HSV1tk lentivirus as described previously. Figure
30 shows HSVtk plasmid map (panel B) and according to the calculations of the band sizes in the
gel electrophoresis result (panel A), the HSV1tk gene is present in the pMOD-HSV1tk vector.
To make sure the HSV1tk gene expresses HSV1TK enzyme, the Ecoli was lysed and western blot
assay was performed as shown in figure 31. HSV1TK enzyme bands are clearly observed at 7,
10, 13 µg of the total protein of the Ecoli lysate. Based on this result this plasmid vector was
chosen to construct the HSV1tk lentivirus.
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Figure 30 panel A gel electrophoresis result, panel B pMOD-HSV1tk map. According to the
standard size of DNA ladder and the pMOD-HSV1tk plasmid map, HSV1tk gene showed the
exact size as shown in the map .The size of linearized plasmid DNA is 3280bp, size of DNA
fragments from digested DNA with Nco-I and Nhe-I are 1255-116=1139 (single cut), 32801139=2141 (double cut).

50 KD
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HSV1TK
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Figure 31 western blot result of pMOD-HSV1tk Ecoli lysate showed HSV1TK enzyme of
different masses from total protein of Ecoli lysate.
HSV1 TK protein was purified from pMOD-HSV1tk Ecoli to be used as a positive control for
western blot assays. Different concentrations of the primary antibody and different amounts of the
protein were tested by western blot to choose the right mass of protein that can be loaded for
western blot assays (figure 32).
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Figure 32 western blot result of purified HSV1TK enzyme, panel A 2µg of HSV1TK enzyme
was tested against different concentrations of primary antibody. To obtain single band without
nonspecific binding 1:10,000 concentration was selected for the following western blot assays
(panel A). Panel B different masses of HSV1TK enzyme were tested against the chosen primary
antibody concentration. Panel C showed HSV1TK signal quantification at different masses. Based
on these findings 0.5 µg was selected for following western blot assays.

5.2.2.2. Selection of stable transduced Jurkat, HEK 293 and 4T1 cells
Before T lymphocytes were transduced with HSV1tk lentiviral vector, stable transduction was
performed with HEK 293, Jurkat and 4T1 cell lines. These cells can be cultured for long periods
of time; therefore they are suitable to be selected using Blasticidin selection marker, which
requires 14 days of incubation. T lymphocytes on the other hand are a primary cell line and they
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can be cultured only for 10 to 13 days. The reason to create stable cell lines was to compare the
uptake of T lymphocytes to stable transduced Jurkat cells and estimate the transduction efficiency
of T lymphocytes based on that.
To create stable cell lines, cells were first incubated with different concentrations of Blasticidin
for 14 days as described previously. This experiment was done to select the optimum
concentration that will end up with zero viability of non-transduced cells. This optimum
concentration was chosen to select stable transduced cells post transduction.
Figures 33, 34 and 35 presented the % of viability of Jurkat, HEK and 4T1 cells respectively.
Jurkat cells showed 0% of viability at 2µg/ml of Blasticidin concentration at day 14 of incubation,
while HEK cells were more resistant, they were at 0% of viability at 10µg/ml at day 14. 4T1 cells
showed 0% of viability at 8µg/ml concentration at day 14.
These concentrations were chosen for stable transduction selection and were added to cells on day
5 post transduction. Cells were incubated at the selected concentration of Blasticidin for more
than one month. RT-PCR and western blot assays were performed on the transduced cells post
Blasticidin selection.
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Figure 33 Panel A bright field images taken by fluorescent microscope of Jurkat cells at different
concentrations of Blasticidin, cells are not able to proliferate and produce colonies in Blasticidin
compared to 0 concentration. Panel B the % of viability of jurkat cells at different concentrations
of Blasticidin on days 3 and 14 of incubation. At 2µg/ml on day 14 of incubation cells were at 0%
of viability.
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Figure 34 panel A bright field images of HEK 293 cells. The % of viability of HEK 293 cells at
different concentrations of Blasticidin on days 7 and 14 of incubation (panel B), even at 8µg/ml of
Blasticidin concentration on day 14 of incubation, cells showed about 11% viable cells. Panel C,
cells were incubated with 0 and 10 µg/ml of Blasticidin and the viability was tested on days
3,7,10 and 14 post incubation. The 0% of viability for HEK cells was at 10µg/ml on day 14 of
incubation.
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Figure 35 panel A bright field images of 4T1 cells at different concentrations of Blasticidin. Panel
B the % of viability of 4T1 cells at different concentrations of Blasticidin on days 1, 7 and 14 of
incubation. At 8µg/ml on day 14 of incubation
cells were at 0% of viability.
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5.2.2.3. Verfication of HSV1tk gene expression by RT-PCR and westren blot
To verify that Jurkat , HEK 293 and 4T1 cells are transduced with HSV1tk, RT-PCR and westren
blot assays were performed as described previuosly. Figure 36 shwed RT-PCR result of the three
cell lines.
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Figure 36 Panel A RT-PCR result showed HSV1tk gene in the transduced cells. Lane 1 and 2
used as positive controls. Lane 1 is the pMOD-HSV1tk DNA (bacterial vector), lane 2 is pLenti6UBC-V5-HSV1tk (viral vector). Acording to the DNA ladder both lanes are between 1.6 and 1 kb
and the expected size is 1.2 kb. Lane 3 Jurkat cell cDNA control, Lane 4 Jurkat cell cDNA
transduced with HSV1tk lentivirus. Lane 5 HEK cell cDNA control. Lane 6 HEK cell cDNA
transduced with HSV1tk lentivirus. Lane 7 4T1 cell cDNA control. Lane 8 4T1 cellcDNA
transduced with HSV1tk lentivirus. Panel B the expression ratio of HSV1tk/Beta Actin, JC=
Jurkat cells, C= control, TD=transduced. 4T1 cells exhibit the higher ratio compared to jurkat and
HEK cells. There is significant differenc between transduced 4T1 and both Jurkat and HEK ( p<
0.05) but no significant difference between Jurkat and HEK cells.

110

A
50 KD
37 KD

HSV1-TK
41 KD

1

Normalized Signal (x103)

B

2

3

4

5

6

7

6
5
4
3
2
1
0
J cells

HEK cells

4T1 cells

Figure 37 western blot result showed HSV1-TK enzyme expressed in the transduced cells.
1 = the purified HSV1TK protein, 2 = untransduced jurkat cells, 3 = transduced jurkat cells, 4 =
untransduced HEK cells, 5 = transduced HEK cells, 6 = untransduced 4T1 cells, and 7 =
thransduced 4T1 cells (300µg of total protein of cell lysate was loaded) (panel A).
Panel B showed the normalized signal of HSV1TK to beta-actin.
5.2.2.4. 124 I [ FIAU ] uptake by transduced Jurkat, HEK 293 and 4T1 cells
The uptake of

124

I-[FIAU] by transduced Jurkat, HEK 293 and 4T1 cells was investigated by

incubating these cells with 124 I-[FIAU] for 1, 2, 4 and 18 hours as described previously. Figure 38
panels A, B and C demonstrated the uptake results of these cells. Transduced Jurkat cells showed
gradual increase in the uptake which was most pronounced at 18 hours (panel A). For HEK cells
there was no significant differences in its uptake at 1, 2 and 4 hours, but was more obvious at 18
hours (panel B). 4T1 cells showed higher uptake at all time points, they showed the maximum
uptake among the three cell lines (panel C).

111

A

B
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Figure 38 [124 I] FIAU uptake in transduced Jurkat cells (panel A), HEK cells (panel B) and 4T1
cells (panel C). 4T1 cells showed the maximum uptake among the three cell lines at the different
time points.
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5.2.2.5. PET imaging of 4T1 tumor
Transduced 4T1 tumor was implanted in a number of animals and imaged at different time points
as shown in figure 39.

25µci/gm

0.25µci/gm

25µci/gm

0.25µci/gm

Figure 39 4T1 wild type tumor (A, B) on the left flank of a mouse imaged 1 hour (A) and 24
hours (B) post injection of 124I-FIAU, shows the radiotracer completely clearing from the tumor
(2.87 %ID/g to 0 %ID/g ). Whereas, the HSV1-tk stably transduced 4T1 tumor (C, D) in the left
flank of another mouse shows the tumor activity to retain the radiotracer from 2.54 %ID/g at 1
hour (C) to 1.05 %ID/g after 24 hours (D). Also seen are the stomach (3.83 %ID/g) and the
thyroid (21.2 %ID/g).

5.2.2.6. T-lymphocytes transduction
5.2.2.6.1. T lymphocytes proliferation and viability before and after transduction
IL2 or IL7/15 T lymphocytes were transduced on day 3 post ex vivo activation and expansion
with different MOIs (10, 5, 2, 1, 0.2 and 0.03) as described previously.
At MOI of 10, the viability of T cells was very low (almost 90% of cells died). At MOI of 5 and
2, the % of viability was less than 40% (figure 40 panel A). However at MOI 1, 0.2 and 0.03,
the % of viability was in average of 80% (figure 40 panel B). Cell proliferation was assessed by
calculating the fold increase in cell number (comparing cell number every other day post
113

transduction to the cell number immediately post activation by B/I). Figure 40 demonstrates cell
proliferation of IL2 or IL7/15 cells at MOI of 1. There are no significant differences (p > 0.05)
between transduced and untransduced cells post transduction. Based on this result, MOI of 1 was
chosen for the following experiments.
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Figure 40 the % of viability of IL2 or IL7/15 at MOI of 2 and 5 (panel A), cell viability at MOI of
2 decreases to less than 60% on day 3, 6 and become about 20% on day 9 post transduction.
While at MOI of 5 at days 3, 6 and 9 decreases to be less that 30%. At MOI of 1, 0.2 and 0.03 the
average viability about 80% (panel B).
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Figure 41 fold increase in cell number for transduced (TD) and untransduced (UNTD) IL2
or IL7/15 cells at MOI of 1(transduction was done on day 3 post ex vivo expansion). No
significant differences between TD and UNTD cells.

5.2.2.6.2. Confirmation of HSV1tk gene expression in transduced T cells
Based on the viability results, transduced cells at MOI of 1, 0.2 and 0.03 were analyzed using
quantitative real time-PCR and western blot on day 5 post transduction to verify that HSV1tk
gene has been integrated to cells genome via the lentiviral vector. Figure 42 shows the expression
ratio of HSV1tk to Beta Actin; at MOI of 1, IL2 cells showed the highest expression ratio and it is
significantly different (p<0.05) from IL2 cells at MOI of 0.2, 0.03 and IL7/15 cells at all three
MOIs. With IL7/15 cells at the three MOIs showed no significant differences in the expression
ratio.
To test the HSV1tk expression, T cells lysate was prepared from IL2 or IL7/15 cells. Total protein
in the cell lysate was determined using protein assay kit, and then 300µg was used for western
blot assay (figure 43).
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Figure 42 the expression ration of HSV1TK to Beta actin in IL2 or IL7/15 cells at different MOIs.
At MOI of 1 IL2 cells shwed the higher expresion ratio. While IL7/15 cells showed almost same
ratio for all MOIs.
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Figure 43 western blot results of transduced IL2 or IL7/15 cells at MOI of 1, 0.2 and 0.03.
Based on the linear relationship of the purified HSV1TK (panel C) the HSV1TK mass was
calculated as illustrated in panel D. IL2 cells at MOI of 1 showed the highest expression of
HSV1TK and this result is consistent with RT-PCR result.

To know the changes in the HSV1tk expression over time, RT-PCR was performed on day
1, 3, 5 and 7 post transduction at MOI of 1 as described previously. The result showed that the
highest expression for both IL2 and IL7/15 cells was at days 1 to day 3; after that the expression
decreased with time (figure 44). IL2 cells showed higher expression than IL7/15 cells on days 1
and 3 while on days 5 and 7, both cells were similar in their gene expression.
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Figure 44 the expression ratio of HSV1tk to Beta Actin at days 1, 3, 5 and 7 post transduction.
IL2 cells showed higher expression than IL7/15 cells. Moreover day 1 and day 3 showed the
higher expression for both cells. Based on this result transduced cells were used for the in vivo
and ex vivo studies on day 3 post transduction.
5.2.2.6.3. Interferon- γ protein release before and after T cell transduction
To test if there are any differences in the ability of IL2 or IL7/15 cells to produce interferon- γ
before and after transduction, interferon-γ release assay was performed on day 3 post transduction
at MOI of 1 as described previously. Figure 45 represents the result; IL2 cells produce more
interferon-γ protein than IL7/15 cells. This result is consistent with our previous result when we
tested the effect of DiR labeled cells on cell protein production. Moreover, there are no significant
differences (p > 0.05) in the amount of the interferon-γ released from cells before or after
transduction. However there are significant differences between nil cells and control (C) or
transduced (TD) cells (Nil cells are T cells incubated alone, control cells are untransduced or
transduced cells incubated with irradiated 4T1 tumor cells).

118

1200

INF-γ (pg/ml)

1000
800
600
400
200
0
IL7/15 C

IL7/15 C IL7/15 TD IL7/15 TD
Nil
Nil

IL2 C

IL2 C Nil

IL2 TD

IL2 TD Nil

Figure 45 the production of interferon γ protein from transduced and untransduced cells.
Nil is stated for cells that were incubated alone. Other cells were incubated with 4T1 tumor cells
to stimulate cell to release interferon γ in their supernatant. No significant differences (p<0.05)
were observed before and after transduction for both cell groups.
5.2.2.6.4. Cell phenotype before and after T cells transduction
Cell phenotype was tested by flow cytometry before and after transduction to investigate if there
is any effect of the transduction on cell phenotype. On day 3 post transduction (MOI=1), cells
were double stained for either CD8/CD69 or CD8/CD62L. CD8 is the marker for cytotoxic T
cells, CD69 is the marker for activated T cells and CD62L is also called L-selectin acts as a
"homing receptor" for T lymphocytes to enter secondary lymphoid tissues via high endothelial
venules. IL7/15 cells showed higher population of activated cytotoxic T cells than IL2 cells. No
significant differences (p<0.05) between transduced and untransduced cells in the % of
CD8/CD69 or CD8/CD62L populations was observed (figure 46).

119

13.6%

51.6%

14.9%

53.5%

29.3%

5.5%

26.3%

5.3%

CD69

CD8
Un transduced IL7/15 cells
Transduced IL7/15 cells
stained for CD8/CD69

24.4%

17.2%

55.1%

3%

37%

17.5%

43.3%

2.3%

CD69

CD8
Un transduced IL2 cells
Transduced IL2 cells
Stained for CD8/CD69

23.3 %

45.1%

23.6 %

42.7%

CD62L

16.4 %

15.1%

17.6 %

16.1%

CD8
Un transduced IL7/15 cells
Transduced IL7/15 cells
stained for CD8/CD62L

120

32.2 %

16.8%

33.3 %

17.1%

6.5%

40.5 %

8.1%

CD62L

43.5 %

CD8
Un transduced IL2 cells
Transduced IL2 cells
Stained for CD8/CD62L

Figure 46 flow cytometry of IL2 and IL7/15 cells phenotype before and after transduction stained
for CD8/CD69 or CD8/CD62L. No significant difference between transduced and untransduced
cells for both cell groups (the % population of positive staining for CD8/CD69 or CD8/CD62L
indicated in blue color).
5.2.2.6.5. [ 124I] FIAU uptake by T lymphocytes
To test the HSV1TK activity, transduced T cells (at MOI of 1 at day 3 post transduction) were
incubated for 1,4, and 18 hours with [124I]-FIAU at activity of 1µci/ml. Figure 45 showed the
uptake result. Transduced Jurkat cells were test along with transduced T cells. The uptake of IL2
and IL7/15 cells looks comparable but less than transduced Jurkat cells. The reason is that the
transduction efficiency of Jurkat cells is 100%

as they were incubated with Blasticidin for

selection more than one month as described previously (they are 100% transduced). While the
transduction efficiency of T cells is lower than 40% compared to Jurkat cells as demonstrated in
the uptake result (figure 47). The HSV1TK protein concentration was assessed after

124

I [FIAU]

uptake by lysate cells and calculate the total protein concentration using protein assay kit as
described previously. Figure 48 showed the result, Jurkat has a higher concentration than
transduced T cells.
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Figure 47 the % uptake of [ 124I] FIAU by transduced T cells along with stable transduced jurkat
cells. the transduction effecency of Jurkat cells is 100 % while T cells compared with Jurkat cells
shwoed less the 40% of cells are transduced.
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Figure 48 transduced cells protein (total cell protein including HSV1TK) concentration post [ 124I]
FIAU uptake. Jurkat cells (TDJC) showed higher protein concentration than T cells especially at
18 hours. There is significant differences (p<0.05) between protein concentration of Jurkat
compared to T cells at 18 hours.
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5.2.2.6.6 Biodistribution study
Transduced T cells were labeled with DiR and injected into 12 animals bearing 4T1 tumor (6 for
IL2 cells and 6 for IL7/15). Another two groups of animals (4 in each) were injected with DiR
labeled T cells to be used as controls for PET imaging and biodistribution study. Fluorescent and
PET imaging were carried out for two weeks. Animals were dissected for biodistribution study on
day 3 and day 10 post

124

I [FIAU ] ( i.v. injections at activity of 200-300 µci / animal). All

tissues were taken for counting by gamma counting system. On day 3 both IL2 and IL7/15 cells
showed similar % injected dose/tissue (%ID/tissue); spleen was the highest then liver, lymph
nodes, tumor, and bone/bone marrow (femur + sternum) (figure 49 panel A). The DiR animal
groups were dissected for counting (panels B and C). In both DiR groups (IL2 or IL7/15) %
ID/tissue was very low compared to transduced (TD) IL2 or IL7/15 groups. This was expected,
because DiR groups are animals were injected with untransduced DiR cell.
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Figure 49 biodistribution study of transduced IL2 and IL7/15 animals on day 3 post 124I [FIAU ]
injections (panel A). Both groups show similar %ID/tissue in all tissues. Panel B and C both
groups were compared to DiR group. There are significant differences between TD groups and
DiR groups (p< 0.05) in %ID/tissue in all tissues. Values expressed as %ID/gm ± SEM (n=3).
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5.2.2.6.7 Detection of HSV1TK at different organs by western blot
To confirm the localization of transduced T cells at tumor site and other organs as shown in the
Biodistribution study, western blot was performed to detect HSV1TK enzyme as shown in figure
50.
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Figure 50 the western blot result of organs post transduced T cell injections.
1= lymph nodes, 2= 4T1 tumor, 3= lungs, 4= liver, 5= spleen and 6= control tumor (from animals
not injected with untransduced T cell). HSV1TK enzyme is clearly shown at these organs beside
the tumor which is consistent with the fluorescent data and Biodistribution study result. (green
color is Beta Actin, and red is Viral Thymidin Kinase (VTK))
5.2.2.6.8 4T1 tumor metastasis and T cells trafficking study.
Our objective from this study is to compare the trafficking pattern of T cells to the primary tumors
versus tumor metastasis. As explained previously, 4T1 tumor cells were transduced successfully
with HSV1tk RG and implanted in number of animals at the abdominal mammary fat pad or in
the right flank of the animal. Unfortunately tumors in the fat mammary pad did not grow well
compared to untransduced cells implanted as a control into the left flank of the animals and most
of the tumor was necrotic. Tumor volume measurements (figure 51) showed that fat mammary
pad tumors (transduced 4T1 cells) did not grow well compared to the control tumor in the left
flank of the animal consequently, no metastases were detected in PET imaging post [

124

I] FIAU

injections in the third and fourth weeks post tumor implantation. On the fourth week post tumor
implantation and post 24 hours of [ 124I] FIAU injections, Biodistribution study was conducted as
shown in figure 52 (A and B). As explained before the activity at each organ expressed
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in %ID/gm of tissue. Intestine showed the highest %ID/gm then liver and stomach due to the
clearance of [

124

I] FIAU from the body. Only the right flank tumor showed higher %ID/gm

compared to the wild type tumor (left flank tumor) (figure 52 A) and also the mammary fat pad
tumors showed about 2% of %ID/gm may some tumor cells are alive and still express HSV1TK

Tumor Volume mm3

protein (figure 52 B).
3500

Day 8

3000

Day 15

2500

Day 17

2000

Day 26

1500
1000
500
0

Figure 51 tumor volume measurements at different time post transduced and untransduced 4T1
tumor implantation. Abdominal mammary fat pad (MFP) did not grow
Well compared to left and right flank tumors.
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Figure 52 Biodistribution studies at 24 hours post 124I FIAU injections. Panel A Biodistribution
study from animals that had MFT tumors in the abdominal region. High % ID/gm was detected at
the intestine, liver, stomach and tumor. Panel B Biodistribution study from animals implanted
with flank tumors. The right flank tumor (transduced tumor) showed higher %ID/gm than the left
flank tumor (wild type tumor). Values expressed in %ID± SEM.

Along with the Biodistribution study, western blot was performed from tumor, spleen, liver,
lungs, brain and lymph nodes. The result (figure 53) showed HSV1TK protein only in the tumor
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tissues and not in the other tissues, indicating, no TK 4T1 (transduced 4T1) cells localized at
these organs.

1
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5

6

7

8

Figure 53 western blot result of tissues after 4 weeks of transduced 4T1 tumor implantation in the
abdominal mammary fat pad. 1 is the purified HSV1TK protein, 2 is wild type 4T1 tumor, 3 is
transduced 4T1 tumor, 4 to 8 are lungs, brain, lymph nodes, liver and spleen.
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Chapter Six:Discussions
This study demonstrates two different labeling methods to monitor T lymphocytes that
are sensitized to 4T1 breast carcinoma tumor, then activated and expanded in vitro and adoptively
transferred to recipient mice. First method is direct labeling with NIR probe (DiR) for optical
imaging. Although the use of DiR as a labeling probe for in vivo studies in AIT is still in its initial
experimental stages; several studies have been successfully applied DiR to label cells and gather
useful information about cell migration and localization in vivo in mice and rats. Kalchenko et al
[64] successfully used DiR to label human leukemia G2L cells, mouse T lymphocytes, and rat red
blood cells for in vivo studies, Granto et al [65] also used DiR to label fibroblast cells to target
ovarian cancer. In another study by Jing Ruan et al [66], used DiR to label embryonic stem cells
to target gastric cancer and they found that this labeling technique has great potential in molecular
imaging application to track cells in vivo. The properties of NIR-DiR as lipophilic dye make it
ideal for staining cytoplasmic membrane. The conclusion of these different studies and other
studies used DiR to label and track different cells showed that DiR had no significant influence on
the biological properties of cells.
In this study we have used DiR to label ex vivo activated T lymphocytes grown in
different cytokines (IL2 or IL7 and IL15) and monitor their migration and trafficking in vivo at
different time points as shown in our results. Cell viability, proliferation and the production of
interferon-γ cytokine were assessed before and after labeling with DiR. The results of these
assays showed that DiR is a compatible probe for cell labeling and in vivo monitoring and does
not cause any changes in cell proliferation, viability or function.
Our in vivo studies showed that, the localization of 4T1 tumor specific T-lymphocytes
occurred within 24 hours after intravenous administration of the activated cells. Although cells
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grown in IL2 showed detectable signal starting from 2 hours (figure 21 A) while for cells grown
in IL7/15, the signal was seen at 24 hours. Smironv and his colleagues [61] studied in vivo T cell
trafficking by direct labeling with SPIONs for MRI imaging. Their results showed relatively
lower signal in the spleen at 24 hours than at 48 hours. The signal at spleen and tumor then
peaked at 72 hours. This result was consistent with our results, both IL2 and IL7/15 cells peaked
at the tumor site at 72 hours. In another study done by Pittet and colleagues [67] it was shown that
tumor specific cytotoxic T-lymphocytes directly labeled with [111In]- Oxine (2.8 days half-life)
for SPECT imaging, started localizing at the tumor site within the first 24 hours and continued to
increase over time and were at peak when imaged at 72 hours post injection. Our results are
consistent with these results; and moreover, the NIR signal from the T-cells at the tumor site
persisted for nearly three weeks after labeling and administration. This demonstrates the
suitability of this method for relatively long-term studies of cell trafficking in animal models of
disease.
To confirm that the signal we observed at the tumor site is associated with DiR labeled T
lymphocytes, cell lysate was prepared using freezing and thawing protocol following viability test
to ensure all cells were lysed, then cell lysate was injected i.v. in number of animals at the same
experiment viable cells were also injected i.v. to another group of animals. MSFI was carried out
at different time points; the result showed that no signal was detected at the tumor site in the
animal group injected with cell lysate. This confirms two important points: first the specificity
and persistence of DiR as labeling probe for T cells, second, the specificity of viable 4T1 specific
T cells to localize at the tumor site. Moreover, to test 4T1 specific T cells specificity toward 4T1
tumor, Meth A tumor was used as control tumor and from our results no localization of 4T1
specific T cells was observed at Meth A tumor. This specificity has been shown in a number of
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studies that used different cytokines to activate ex vivo T cells isolated from tumor or draining
lymph nodes (DLN) then adoptively transferred to tumor bearing hosts which cause regression of
the tumor over specific period of time [68]. In our studies we used DLN T cells activated in
Bryostatin 1 and Ionomycin (B/I) for 18 hours then grown in different cytokines (IL2 alone or
combination of IL7 and IL15) for 10 to 12 days. This activation method has been shown by
Esther Cha et al [26] for AIT in 4T1 breast tumor and by Hanh et al [23] for AIT in B16
melanoma tumor and their results showed significant regression of tumor depending on
adoptively transferred cell number. Bryostatin 1 selectively activates protein kinase C and
Ionomycin increases intracellular calcium with both mimicking cell signaling through CD3 T cell
receptor (TCR) and leading to activation and proliferation of T cells. Chin et al [69] has shown
that tumor sensitized draining lymph nodes (DLN) cells activated ex vivo with B/I are capable of
inducing antigen-specific regression in murine mammary tumors. The same group demonstrated
that B/I selectively stimulates and activates T cells expressing low levels of lymph node homing
receptor (L-selectinlow ) or ( CD62Llow) which is a marker associated with sensitized T cells and
promote their trafficking to other locations [70].
We also observed that the labeled T-cells home into lymphoid organs such as bone
marrow and spleen, from ex vivo imaging of dissected organs. In order to examine whether these
labeled T-cells are capable of moving out of these compartments and home into a tumor site at a
subsequent tumor challenge, in one set of experiments, we first injected the labeled 4T1 specific
T-cells in non-tumor bearing mice. One week later, these animals were imaged just before and
then after the 4T1 tumor cells were implanted. DiR labeled 4T1 specific T-cells were detected in
the tumor cell injection site as early as 2 hours after tumor cell implantation. The signal at the
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tumor site persisted for another two weeks, confirming that the labeled T-cells can move out of
the lymphoid organs to the site of a fresh antigen challenge.
Labeling of T-cells with near-infra red (NIR) fluorescent dyes for AIT has been reported
in a few recently published studies. Du and coworkers [71] investigated the trafficking of DiR
labeled human cytokine-induced killer (CIK) cells and cytotoxic T lymphocytes (CTLs) in a nude
mouse model of orthotopic gastric carcinoma. In their study, the fluorescent signal peaked at 48
hours and was observed at the tumor site up to two weeks after infusion. The cell proliferation of
labeled cells was comparable to unlabeled cells, similar to our observations. Moreover, after
labeling the T-cells with a range of DiR concentrations (3.5, 14, 56, 224 and 320 µg/ml), we
tested the cell viability using two different methods to ensure good cell tolerance to the dye before
moving to the in vivo studies. T-cell function was also tested by measuring IFN-γ release in
response to tumor antigen, and our results showed no significant detrimental effect of the labeling
probe on cell proliferation, viability or function. Also, this allowed us to use a high DiR
concentration (320 µg/ml) in the labeling solution. Our study also demonstrates signal persistence
in the labeled T-cells even 3 weeks post labeling under the in vivo conditions of living mice.
The in vivo biodistribution of the labeled T-lymphocytes, in this study, was consistent with
other studies. The signal was detected in lungs, spleen, liver, bone marrow and was observed at
the tumor site at 24 hours and remained stable for up to 21 days when the labeled cells were
infused into mice bearing established 4T1 breast carcinoma tumors. To ascertain whether the
source of signal around the tumor was coming from labeled T-cells, double staining of tumor with
CD69 (T cell activation marker) and F4/80 (macrophage marker), was performed. The confocal
microscopy images revealed presence of activated T cells only in sections from mice bearing 4T1
tumor injected with ex vivo activated T cells and not in tumor sections from control 4T1 bearing

132

mice. On the other hand, the presence of macrophages was observed in tumor sections from both
groups of animals as expected. Moreover, flow cytometry method was used to investigate whether
DiR labeled T cells were engulfed in vivo by macrophages or DiR transferred to other immune
cells. The result showed that no connection between DiR and macrophages or other immune cells,
representing that DiR specifically labeled ex vivo activated T cells and the signal we detected is
linked to only DiR labeled T cells.
In conclusion, this method shows that, labeling of 4T1 specific T lymphocytes with DiR, a
NIR fluorescent cell membrane marker, provides an easy to use, stable and convenient tool for in
vivo imaging of T-lymphocytes whilst retaining their inherent function. Use of DiR or similar cell
membrane markers will be useful for investigating lymphocyte trafficking following their ex vivo
sensitization, activation and proliferation. This method could also be used to non-invasively
monitor the trafficking of other cell types.
The second method in this study was indirect labeling of T cells using PRG system
(HSV1tk/ [124I]-FIAU). Initially HSV1tk gene was used as therapeutic or suicide gene in the
application of gene therapy studies for different types of cancer. The first approaches developed
to introduce HSV1tk as therapeutic gene was by Moolten at al [72]. In this approached they used
Ganciclovir (GCV) as substrate for HSV1tk gene which was transduced to a number of tumors.
The result of phosphorylation showed cell toxcicity and death to transduced tumor cells. Since
that time more studies were developed to image HSV1tk/GCV as reporter system for gene
therapy [73]. The principle of in vivo imaging using HSV1tk as reporter gene for imaging was
first demonstrated using

14

C 2- fluoro-5-methyl-1-ß-D- arabinofuranosylluracil ([14C ]-FMAU)

by Saito et al in 1982 [74 ]. Later in 1995, Tjuvajev et al employed ([123/124I ]-FIAU) as reporter
probe for HSV1-tk reporter gene for brain tumors [75]. Subsequently they demonstrated for the
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first time that (HSV1tk/ [124I ]- FIAU) system is highly specific as noninvasive imaging system
for clinical PET imaging due to its ability to image the distribution and the level of gene
expression [76].
FIAU is a thymidine nucleoside has been used as an antiviral agent against hepatitis
viruses [77]. FIAU has advantages of being imaged by different imaging modalities such as
SPECT and PET due the ability of radiolabeling with

123/125/131

I or 124I. Moreover, it is a specific

substrate for viral thymidine kinase (VTK) enzyme that is expressed by HSV1tk gene,
mammalian TK has no ability to phsphorylate FIAU. In comparison to other reporter probes such
as FHBG or FHPG it has greater sensitivity and lower abdominal background radioactivity [78].
In this study we used HSV1tk/ [124I ]- FIAU system for the indirect labeling method of T cells due
its mentioned advantages .
Our results demonstrate successful transduction in Jurkat, HEK293, 4T1 and T cells. This
was confirmed by RT-PCR, western blot and uptake studies. One problem we faced is that the
HSV1tk lentivirus we used showed some toxicity to T cells. This lead us to reduce the ratio of
virus particles to cells number during the transduction; consequently the transduction efficiency
was low and couldn’t be detected by PET imaging. Toxicity of reporter gene imaging has been
shown in a number of studies [79] and it is one of the limitations of this method. Another
limitation is that, the level and persistence of gene expression was not enough to monitor our
transduced T cells. Even though our ex vivo data showed successful transduction of T cells, but
the scenario in vivo was different. Only few cells were transduced and the percentage of cells at
each organ including tumor site was lower than 5% (this was shown in flow cytometry data) from
the total 10 million cells were injected into each animal. Also our reporter gene promoter was an
ubiquitin promoter which has limited amount of gene expression compared to other promoters
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like cytomegalovirus (CMV) promoter. The rationale of using ubiquitin promoter is that it doesn’t
have a silencing problem with time, and our goal was to monitor T lymphocytes for long periods
of time. However our biodistribution data showed results consistent with optical imaging data,
the %ID/gm was higher at spleen, lungs, liver and tumor. Also Western blot assay from these
tissues showed the presence of HSV1TK enzyme at each tissue.
In conclusions, to improve our reporter gene method, more effective HSV1tk lentivirus
has to be constructed. The new constructed reporter gene should include GFP protein as a marker
to accurately estimate cell transduction efficiency. This estimation method is more common and
precise to know the exact percentage of transduced cells using flow cytometry or fluorescent
microscopy. The promoter has to be chosen to result in a sufficient level of gene expression to
successfully obtain good detection of signal for imaging.
The last objective in this study was to monitor the localization of T cells at 4T1 tumor
metastases. To achieve this objective, 4T1 cells were successfully transduced with HSV1tk and
implanted in number of animals at the abdominal mammary fat pad. PET imaging was performed
at third and fourth week post tumor implantation, but no metastases were detected.

From

previous studies [80], abdominal mammary fat pad tumors more likely to spread in the abdominal
region and do not show metastases at other regions of the animal body. Omar Rashid et al [80]
has shown successful 4T1 tumor metastases model by implanting 4T1-luc2 (4T1 transduced
tumor with luciferase reporter gene) orthotopically into chest mammary fat pad of Balb/C mice
under direct vision. After 10 days resection of the primary tumor was done and the tumor
metastases were detected by biolumencent imaging at lymph nodes by day 8 after tumor
implantation then to the lungs by day 12. This method improves animal survival by decreasing
the overall tumor burden, rapid increase in the metastases proliferation; decrease splenocyte
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myeloid-derived suppressor cells (MDSCs) and increasing in CD8 and CD4 cells, suggesting
potential improvement in the immunologic response against the tumor.
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Chapter Seven Conclusion and Future Work
This study was done to develop multi-modality molecular imaging to monitor in vivo 4T1 specific
T cells, for adoptive immune cell therapy. Direct and indirect labeling methods were employed
and studied.
Direct labeling method using NIR DiR florescent probe showed good results compared to the
indirect labeling method using (HSV1tk/ [124I] FIAU) system.
The following points can be highlighted from the indirect labeling method:


This method showed higher labeling efficiency (> 90%) compared to the indirect labeling
method (≤ 30%).



No transfer of the DiR to other cells in vivo and ex vivo was observed.



DiR provides an easy to use, stable and convenient tool for in vivo imaging of Tlymphocytes whilst retaining their inherent function in vivo and ex vivo.



In comparison to the indirect labeling method, direct labeling method showed valuable
information about the trafficking and localizations of T cells grown in different cytokines



Indirect labeling method is limited by targeting or delivery of the reporter gene (RG) to
cell under transduction, integration, activation, amount or level of RG (transduction
efficiency), RG expression and persistence over time.

Recommendations and future directions
As the direct labeling method with DiR provides valuable data about the trafficking and
localizations of DiR labeled T cells without any changes in cell proliferation, viability, and
function, it is worthwhile to label DiR with 124I for PET imaging, or
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I for SPECT imaging over

prolonged period of time. To achieve this, the radio-iodination strategy of DiR has to be robust
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and must resist dehalogination in vivo. Furthermore, the effect of radioactivity, per se, on cell
proliferation and viability must be carefully addressed.

To improve the indirect labeling method, more effective HSV1tk lentivirus should be constructed
with GFP to accurately estimate the transduction efficiency. Furthermore, the new construction
should not be toxic at the adequate level for the gene to be detected in the in vivo imaging.

To develop successful breast cancer metastatic model, for the purpose of studying the
migration pattern of labeled T cells to the metastases, it is highly recommended to follow Omer
Rashid et al model [80]. This model as discussed previously improves animal survival by
decreasing the overall tumor burden, rapid increase in the metastases proliferation; decrease
splenocyte myeloid-derived suppressor cells (MDSCs) and increasing in CD8 and CD4 cells,
suggesting potential improvement in the immunologic response against the tumor.
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Appendix
Research publications and conference presentations
Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J.
(2011, 2012 and 2013) Multi-spectral fluorescence imaging of adoptive immune cell therapy
using cell membrane probe ( presented at the Massey Cancer retreat meetings with adding more
data)
Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J.
(2013) Multi-spectral fluorescence imaging of adoptive immune cell therapy . J. Molecular
Imaging (submitted)

Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J.
(2011 ) Multi-spectral fluorescence imaging of adoptive immune cell therapy using cell
membrane probe .Journal of Nuclear Medicine.52:pp1557.2011( presented at the SNM-2011
meeting).

Georgi Gurli, Gobalakrishnan S., Youniss F, Ekaterine Goliadze , Li Wang, Sammuel P .R
obison, Zweit (2012) Molecular Imaging of dendritic cell tracking in vivo in a murine prostate
cancer model (presented to AUA 2012 meeting)
Youniss F, Ekaterine Goliadze, Gobalakrishnan Sundaresan, Li Wang, Georgi Gurili, Jamal
Zweit. (2013) Non-invasive near-infrared imaging of dendritic cell trafficking in living mice.
( presented to WMIC 2013 meeting as oral presentation)

Submitted predoctoral molecular imaging scholar program application to SNMMI 2012(not
funded)
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